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ABSTRACT 
Cardiovascular disease (CVD) is a complex disease with multifactorial aetiology. 
Both genetic and environmental factors contribute to the disease risk. The lifetime 
risk for CVD differs markedly between men and women, men being at increased 
risk. Inflammatory reaction contributes to the development of the disease by 
promoting atherosclerosis in artery walls.  
In the first part of this thesis, we identified several inflammatory related CVD risk 
factors associating with the amount of DNA from whole blood samples, indicating a 
potential source of bias if a genetic study selects the participants based on the 
available amount of DNA. In the following studies, this observation was taken into 
account by applying whole genome amplification to samples otherwise subjected to 
exclusion due to very low DNA yield. 
We continued by investigating the contribution of inflammatory genes to the risk for 
CVD separately in men and women, and looked for sex-genotype interaction. In the 
second part, we explored a new candidate gene and its role in the risk for CVD. 
Selenoprotein S (SEPS1) is a membrane protein residing in the endoplasmic reticulum 
where it participates in retro-translocation of unfolded proteins to cytosolic protein 
degradation. Previous studies have indicated that SEPS1 protects cells from oxidative 
stress and that variations in the gene are associated with circulating levels of 
inflammatory cytokines. In our study, we identified two variants in the SEPS1 gene, 
which associated with coronary heart disease and ischemic stroke in women. This is, 
to our knowledge, the first study suggesting a role of SEPS1 in the risk for CVD after 
extensively examining the variation within the gene region. 
In the third part of this thesis, we focused on a set of seven genes (angiotensin 
converting enzyme, angiotensin II receptor type I, C-reactive protein (CRP), and 
fibrinogen alpha-, beta-, and gamma-chains (FGA, FGB, FGG)) related to 
inflammatory cytokine interleukin 6 (IL6) and their association with the risk for 
CVD. We identified one variant in the IL6 gene conferring risk for CVD in men and 
a variant pair from IL6 and FGA genes associated with decreased risk. Moreover, we 
identified and confirmed an association between a rare variant in the CRP gene and 
lower CRP levels, and found two variants in the FGA and FGG genes associating 
  
with fibrinogen levels. The results from this third study suggest a role for the 
interleukin 6 pathway genes in the pathogenesis of CVD and warrant further studies 
in other populations. In addition to the IL6 -related genes, we describe in this thesis 
several sex-specific associations in other genes included in this study. The majority 
of the findings were evident only in women encouraging other studies of 
cardiovascular disease to include and analyse women separately from men. 
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TIIVISTELMÄ 
Sydän- ja verisuonisairaudet kuuluvat geneettisesti monitekijäisiin sairauksiin. Sekä 
perinteiset riskitekijät, kuten korkea kolesteroli ja miessukupuoli, että perintötekijät 
altistavat sydän- ja verisuonisairauksille. Tulehdusreaktio liittyy olennaisesti taudin 
kehitykseen vaikuttaen yhdessä muiden riskitekijöiden kanssa valtimoiden 
seinämien ateroskleroosin syntyyn. 
Väitöskirjan ensimmäisessä osassa tunnistimme useita tulehdusreaktioon liittyviä 
sydän- ja verisuonisairauksien riskitekijöitä, jotka ovat yhteydessä kokoverestä eris-
tettävän DNA:n saantoon. Tuloksen perusteella voidaan olettaa, että tutkittavien 
valinta DNA-määrän perusteella geneettisiin epidemiologisiin tutkimuksiin saattaa 
aiheuttaa harhan tutkimusasetelmassa.  
Väitöskirjan seuraavissa osatöissä huomioimme ensimmäisen työn tulokset ja 
monistimme koko genomin kattavalla monistusmenetelmällä DNA-määrän 
lisäämiseksi näytteet, jotka vähäisen DNA-määrän johdosta olisivat joutuneet 
poissuljetuiksi. 
Seuraavaksi tutkimme tulehdusreaktioon liittyvien kandidaattigeenien vaikutusta 
sydän- ja verisuonisairauksien riskiin kahdessa suomalaisessa aineistossa. Toisessa 
osatyössä syvennyimme uuteen mielenkiintoiseen ehdokasgeeniin, selenoproteiini 
S:aan (SEPS1). SEPS1 on kalvoproteiini, joka sijaitsee solulimakalvostossa. Se 
osallistuu väärinlaskostuneiden proteiinien takaisinkuljetukseen solulimaan. 
Aiemmat tutkimukset ovat osoittaneet, että SEPS1 suojaa soluja hapettumisen 
aiheuttamilta vaurioilta ja että geneettinen vaihtelu geenin alueella on yhteydessä 
tulehdusreaktiota välittävien liukoisten sytokiinien pitoisuuksiin verenkierrossa. 
Tutkimuksemme osoitti, että kaksi polymorfiaa SEPS1 geenin alueella nostavat 
koronaaritaudin ja iskemiseen aivohalvauksen riskiä naisilla. Tämä on ensimmäinen 
kansainvälisellä tasolla julkaistu tutkimus, jossa on tutkittu kattavasti geneettistä 
variaatiota SEPS1 geenin alueella ja osoitettu sen vaikuttavan sydän- ja 
verisuonisairauksien riskiin. 
Kolmannessa osatyössä keskityimme seitsemään tulehdusreaktiota säätelevään 
interleukiini 6 (IL6) sytokiiniin liittyvään geeniin (angiotensiiniä konvertoiva 
  
entsyymi, angiotensin II reseptorityyppi I, C-reaktiivinen proteiini (CRP), sekä 
fibrinogeenin alfa-, beta-, ja gammaketjut (FGA, FGB, FGG)). Tutkimuksen 
perusteella IL6 geenin polymorfia on yhteydessä suurentuneeseen sydän- ja 
verisuonisairauksien riskiin miehillä. Lisäksi toinen polymorfia samassa geenissä 
yhdessä FGA geenissä olevan polymorfian kanssa vaikutti suojaavan sydän- ja 
verisuonitaudeilta. Edelleen, yhtenevästi aiempien tutkimustulosten kanssa 
osoitimme CRP geenissä sijaitsevan variantin olevan yhteydessä pienentyneisiin 
CRP pitoisuuksiin sekä tunnistimme kaksi fibrinogeenipitoisuuteen vaikuttavaa 
varianttia FGA ja FGG geeneissä.  
Tulosten perusteella IL6:een liittyvillä geeneillä on vaikutusta sydän- ja 
verisuonisairauksien riskiin ja riskitekijöihin, IL6:n ja sen liitännäisgeenien tarkempi 
rooli sydän- ja verisuonitaudeissa edellyttää kuitenkin lisätutkimuksia muissa 
populaatioissa. Näiden geenien lisäksi, kuvaamme väitöskirjassa useita kolmanteen 
osatyöhön liittyvien geenien yhteen sukupuoleen rajoittuneita assosiaatiolöydöksiä. 
Näistä useimmat esiintyivät naisilla ja korostavat miehillä ja naisilla erikseen 
tehtävän sydän- ja verisuonitaudin tutkimuksen tärkeyttä. 
 
 
 
Avainsanat: Sydän- ja verisuonitauti, assosiaatiotutkimus, suhteellisen vaaran malli, 
tulehdusreaktio, yhden nukleotidin muutos, DNA 
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ABBREVIATIONS 
α Significance level 
ABCA1 ATP-binding cassette transporter A1 
ApoB-100 Apolipoprotein B-100 
ACE Angiotensin converting enzyme 
ACS Acute coronary syndrome 
Ang I Angiotensin I 
ApoE Apolipoprotein E 
AT1R, AGTR1 Angiotensin II receptor type I (protein, gene) 
ATP Adenosine triphosphate 
bp Base pair 
BMI Body-mass index 
CAD Coronary artery disease 
CDCV Common disease, common variant 
CETP Cholesteryl ester transfer protein 
CHD Coronary heart disease 
CI Confidence interval 
CNV Copy-number variant 
CVD Cardiovascular disease 
DNA Deoxyribonucleic acid 
EMSA Electrophoretic mobility shift assay 
ER Endoplasmic reticulum 
ERSE Endoplasmic reticulum stress response element 
FCHL Familial combined hyperlipidemia 
FDR False discovery rate 
FGA, FGB, FGG Fibrinogen alpha, beta, gamma 
FLAP, ALOX5AP 5-lipoxygenase activation protein (protein, gene) 
GWA Genome-wide association 
HDL High-density lipoprotein 
HR Hazard ratio 
HRT Hormone replacement therapy 
hsCRP High sensitivity C-reactive protein 
htSNP Haplotype tagging single nucleotide polymorphism 
I/D Insertion/deletion 
ICAM1 Intercellular adhesion molecule 1 
ICD-10 International Statistical Classification of Diseases and Related 
Health Problems, 10th Revision 
IL-1β Interleukin 1 beta 
IL6 Interleukin 6 
IL10 Interleukin 10 
IMT Intima media thickness 
INF-γ Interferon gamma 
ITGB3 β3 integrin 
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kb Kilo base 
LD Linkage disequilibrium 
LDL Low density lipoprotein 
LDLR Low density lipoprotein receptor 
LGALS2 Galectin-2 
LPL Lipoprotein lipase 
LTA Lymphotoxin alpha 
LTA4 Leucotriene A4 
MetS Metabolic syndrome 
MI Myocardial infarction 
MPRCA Multiply-primed rolling circle amplification 
mRNA Messenger ribonucleic acid 
MTHFR Methylenetetrahydrofolate reductase 
N Number 
NF-κB Nuclear factor kappa-B 
OR Odds ratio 
PAI1 Plasminogen activator inhibitor-1 
PCR Polymerase chain reaction 
RAS  Renin-angiotensin-system 
SAA Serum amyloid A 
SD Standard deviation 
SEPS1 Selenoprotein S 
SNP Single nucleotide polymorphism 
SNPSpD Single nucleotide polymorphism spectral decomposition 
TE Tris-EDTA 
TF Transcription factor 
TIA Transient ischemic attack 
TNF-α Tumor necrosis factor alpha 
UPR Unfolded protein response 
USF1 Upstream transcription factor 1 
UTR Untranslated region 
VCAM1 Vascular cell adhesion molecule 1 
VSMC Vascular smooth muscle cell 
WGA Whole genome amplification 
WHO World Heath Organization 
WHR Waist/hip ratio 
 
Gene names are emphasised with italics in the text.  
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1 INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death among the chronic non-
communicable diseases and poses a significant public health burden worldwide. The 
three major manifestations of atherosclerotic CVD are coronary heart disease 
(CHD), ischemic stroke and peripheral arterial disease. Atherosclerosis develops as 
a result of a complex interplay between endothelial dysfunction, inflammation, and 
coagulation and fibrinolysis. The atherosclerotic plaque can grow either towards the 
vessel lumen or into the vessel wall. Subsequently, if the plaque does not reduce the 
blood flow and oxygen supply to the surrounding tissue, CVD can be completely 
asymptomatic whereas a stenotic plaque often results in angina pectoris. Myocardial 
infarction or ischemic stroke, are consequences of occluding thrombi diminishing 
the blood flow. This most often takes place on the surfaces of non-stenotic plaques.  
CVD is a heritable trait, heritability estimates for CHD and ischemic stroke death 
ranging from 0.3 to 0.6. Thus far many genes and chromosomal regions have been 
suggested as candidates conferring susceptibility to the disease. The common form 
of CVD is a late-onset multifactorial disease, and as with other multifactorial 
diseases, the hunt for susceptibility genes has not been very successful. Consistent 
findings between populations and study samples have been rare until the very recent 
genome-wide association studies. The underlying genes most likely contribute each 
with a small effect and exhibit a wide range of allele frequencies. 
The purpose of this study was to investigate the contribution of selected 
inflammatory genes to the risk for CVD. The incidence of CVD is distinctly 
different between men and women, women being at lower risk, and in this study we 
aimed to investigate the association separately in both sexes and possible sex-
genotype interactions. Since the genes in Study III were selected based on previous 
knowledge of their biological relationships, we also looked for interactions within a 
distinct pathway related to cytokine interleukin 6. Furthermore, given that genetic 
epidemiological studies are vulnerable to many kinds of biases, we wanted to 
investigate one source of potential bias, the association between inflammatory risk 
factors of CVD and the amount of DNA, the molecule to which every genetic 
epidemiological study is based on. The following review will focus on the existing 
knowledge of the genetic background of cardiovascular disease and on available 
strategies to identify genes underlying susceptibility to common forms of 
cardiovascular disease.  
 11 
 
2 REVIEW OF THE LITERATURE 
2.1 Cardiovascular disease 
Coronary heart disease (CHD), ischemic stroke and peripheral arterial disease are 
the three major manifestations of atherosclerotic cardiovascular disease (CVD). In 
the year 2005, CVD was the leading cause of death among the chronic non-
communicable diseases accounting for 30% of all deaths both in Finland and 
worldwide (World Health Organization 2006, Statistics Finland 2007). Although the 
incidence of the disease is declining, ischemic heart disease and cerebrovascular 
disease are projected to continue to be the leading causes of death also for the next 
few decades (Mathers and Loncar 2006). The incidence of CVD differs markedly 
between the sexes: the lifetime risk at the age of 40 for developing CHD is 
approximately one in two for men and one in three for women. The corresponding 
figures for stroke are one in six for men and one in five for women (Tunstall-Pedoe 
et al. 1994, Jousilahti et al. 1999, Lloyd-Jones et al. 1999, Seshadri et al. 2006). 
Moreover, the age-of-onset of CHD is 7 to 10 years higher for women than for men 
(Bello and Mosca 2004).  
Patients with coronary heart disease may be entirely asymptomatic or present a wide 
range of symptoms from chest pain to dyspnea and fatigue (Table 1). Differences in 
symptoms, pathological changes and electrophysiology of the heart divide CHD 
clinically into a) acute coronary syndrome (ACS) including unstable angina pectoris 
and both non-ST and ST segment elevation myocardial infarction (MI) and b) stable 
angina. In clinical practice, it is important to separate the two types of MI and some 
exclude non-ST elevation MI from ACS. In this thesis, it is included when 
discussing ACS. The essential cause of the ACS is the abrupt lack of oxygen supply 
to the heart muscle resulting from a thrombotic occlusion. The thrombotic clot can 
either originate from a distant site, such as the left atrium or carotid artery, or form 
in situ as a result of the clotting reaction. Systemic factors, such as blood 
hyperthrombogenicity or rheology (ie. alterations in the blood flow due to, for 
example, vasoconstriction) can also contribute to the formation of a thrombotic clot. 
Stable angina pectoris is often associated with exertion and is relieved by rest. The 
inability of the coronary arteries to respond to an increased demand for oxygen may 
be due to stenosis in one or more coronary arteries or a vasospasm on a coronary 
artery lesion. (Grant and Humphries 1999, Goldman and Ausiello 2004) 
Stroke is a clinically heterogeneous disease, which is characterized by a neurological 
deficit lasting for more than 24 hours or leading to death. The underlying cause is 
either spontaneous hemorrhage or lack of oxygen due to reduced blood flow leading 
 12 
 
to ischemic cerebral infarction. Atherosclerosis in the carotid arteries is the most 
common aetiology of the ischemic strokes. Other causes include cardioembolism 
and atherosclerosis of the small arteries. If the symptoms of ischemia are only 
transient, the disease is diagnosed as a transient ischemic attack (TIA). The 
symptoms related to cerebral haemorrhage are due to either pressure on surrounding 
tissues or the toxic effects of the blood. (Frizzell 2005) 
 
Table 1. Typical coronary heart disease symptoms. 
Crushing or pressing chest pain or discomfort 
Radiating pain to the left arm, neck or back 
Pain symptoms increasing with exertion 
Palpitations, dizziness, syncope 
Fatigue, weakness 
 
 
In genetic epidemiological studies using registries for event identification, the 
definition of CVD often includes coronary heart disease and ischemic 
cerebrovascular disease but does not include peripheral artery disease and excludes 
hemorrhagic stroke and TIA (Laatikainen et al. 2007). Diagnoses based on the 
International Statistical Classification of Diseases and Related Health Problems, 10th 
Revision (ICD-10) (World Health Organization 2005) for CHD are: I20-I25, I46, 
R96, R98 and for stroke I60-I69, G45. In stroke, atherosclerosis contributes mainly 
to episodes related to ischemia and infarction defined with ICD-10 diagnosis classes 
I63-I64. Table 2 presents, as an example, diagnostic classification from a study 
aiming to identify genetic risk factors for CHD and ischemic stroke based on the 
WHO MONICA project.  
2.1.1 Atherosclerosis – an inflammatory disease 
Atherosclerotic changes in the arteries of the heart, brain and extremities cause 
atherosclerotic cardiovascular disease. A complex interplay between dyslipidemia, 
inflammation, coagulation, fibrinolysis and endothelial dysfunction is involved in 
the progression of the disease. The intima is the arterial wall layer principally 
involved in the development of atherosclerosis, although secondary changes are 
occasionally seen in the media. (Ross and Glomset 1976a, Ross and Glomset 1976b) 
(Figure 1) The atherosclerotic plaque can grow towards the lumen of the vessel or 
deeper into the vessel wall (Libby et al. 2002). An acute myocardial infarction or 
ischemic stroke is a consequence of a thrombus occluding the blood flow. About 
two-thirds of ACS are caused by occlusive thrombosis on a non-stenotic plaque, and 
in about one-third, the thrombus occurs on the surface of a stenotic plaque (Falk et 
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al. 1995). The development of atherothrombosis is a complex process and detailed 
molecular mechanisms of all the different stages are yet to be fully characterised. 
However, the key steps in the pathogenesis of the disease are known.  
 
Table 2. Diagnostic classification of fatal and non-fatal cardiovascular disease events. An 
example from a genetic epidemiological study in Finland. The classification is based on the 
recommendations by the WHO MONICA project. 
Disease classification ICD-10a Non-fatal Fatal 
Coronary events    
Unstable angina I20.0 x  
Acute myocardial infarction I21 x x 
Subsequent myocardial infarction I22 x x 
Certain current complications following  
    acute myocardial infarction 
I23  x 
Other acute ischaemic heart diseases I24  x 
Chronic ischaemic heart disease I25  x 
Cardiac arrest I46  x 
Other sudden death, cause unknown R96  x 
Unattended death R98  x 
Other ill-defined and unspecified causes of mortality R99  x 
Stroke events    
Cerebral infarction I63 x x 
a ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision 
  Based on Komulainen et al. 2006. 
 
Injury or dysfunction of the endothelium is a key event in the evolution of 
atherosclerotic plaques. Atherosclerosis develops in the blood vessels at the site of 
low sheer stress such as curvatures, bifurcations and branch points (Feldman and 
Stone 2000). At these sites, the shape of the endothelial cells has transformed from 
an elongated to a more rounded shape with discontinuous tight junctions, irregularly 
shaped gap junctions and a lack of zonular type of tight junctions, which prevent 
permeation of serum proteins. These abnormalities may indicate endothelial 
dysfunction and activation that leads to increased intracellular permeability (Okano 
and Yoshida 1993, Yoshida et al. 1995). It has also been shown that lipid deposits 
are more likely to form in low shear stress areas than in areas of elevated shear stress 
(Zand et al. 1999). Together with other risk factors, such as increased blood 
pressure, elevated cholesterol levels, toxic substances from tobacco smoking, 
advanced glycation end products associated with diabetes mellitus, vasoactive 
amines and immune complexes – shear stress forces induce endothelial dysfunction. 
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Endothelial dysfunction is linked fundamentally to the initial formation of 
atherosclerosis via increased permeability of the endothelium, reduced generation of 
nitric oxide and elevated expression of adhesion molecules; it facilitates vessel wall 
entry and oxidisation of circulating lipoproteins, as well as infiltration of monocytes 
and other cells of the immune system (Fuster et al. 2005). In high concentrations, the 
lipoproteins, particularly low-density lipoprotein (LDL) particles, are trapped in the 
intima. Self-aggregation of LDL particles and interactions between proteoglycans 
and extracellular matrix proteins with apolipoprotein B 100 (APOB), apolipoprotein 
E (APOE) or lipoprotein lipase (LPL) further facilitate their retention (Khalil et al. 
2004). Once in the intima, they are modified in many ways: they form complexes 
with proteglycans and immune cells, become oxidized, hydrolysed and glycated, 
proteolysis degrades the apoB-100 molecules, and other enzymes further modify 
LDL particles to form cholesterol-enriched lipid droplets. These modifications, 
particularly minimally oxidised LDL, stimulate endothelial cells to secrete pro-
inflammatory and adhesion molecules, and monocyte chemotactic protein 1 that 
facilitate the recruitment and transmigration of monocytes and lymphocytes to the 
arterial wall. Oxidation also makes LDL recognisable to macrophage scavenger 
receptors leading to their internalisation and macrophage cholesteryl ester 
accumulation, i.e. foam cell formation. (Tabas 1999)  
The size of the LDL particle appears to play a role in defining the atherogenic 
properties of the lipoprotein: LDL is the principal cholesterol-carrying lipoprotein in 
the plasma but also larger particles, such as chylomicrons and very-low-density 
lipoprotein can be atherogenic, especially their remnants (Krauss 1998). It seems, 
however, that small sized LDL particles are more atherogenic than particles with 
larger size and confer greater CVD risk (Austin et al. 1988, Veniant et al. 2001). 
High-density lipoprotein (HDL) balances this atherogenic process by removing 
cholesterol from the arterial intima macrophages via a process of reverse cholesterol 
transport and by preventing LDL oxidation via HDL-associated paraoxonase activity 
(Reddy et al. 2001). The accumulation of modified lipids and inflammatory cells 
leads to formation of a fatty streak, the early stage of atherosclerotic lesion.  
Fatty streaks are already present in early childhood and adolescence and start to 
develop into more advanced lesions in early adulthood (McGill et al. 2000). A 
fibrous lesion has characteristically an increasing pool of lipids released from the 
apoptotic macrophages and it accumulates vascular smooth muscle cells (VSMC) 
and VSMC-derived extracellular matrix over the core region of lipid droplets and 
foam cells. Dendritic cells, mast cells and a small number of B cells are also present 
in the plaque. (Jonasson et al. 1986, Hansson and Libby 2006) Inflammation is 
crucially involved also in the progression of the fibrous plaques. Inflammatory cells, 
macrophages and T-lymphocytes continue to infiltrate to the lesion and proliferate at 
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the site. Macrophages secrete cytokines (i.e. interleukin 1β (IL-1β), interleukin 6 
(IL6), interleukin 8, tumor necrosis factor alpha (TNF-α)), chemokines and growth-
regulating molecules. These signalling molecules stimulate VSMCs to increase their 
proliferation rate, to migrate to the site of inflammation and to produce extracellular 
matrix. (Ross 1999)  
Of the lymphocytes, Th1-type T cells, that secrete pro-inflammatory cytokines 
interferon-γ (INF-γ), TNF-α, and interleukins 12, 15 and 18, is the class most 
frequently found in the lesion. Other important inflammatory mediators are the cell-
surface proteins CD40 and CD40 ligand. In addition to T and B cells, macrophages, 
endothelial cells, VSMCs and platelets also express CD40 (Mach et al. 1997, Henn 
et al. 1998). Like pro-inflammatory cytokines, CD40 ligation triggers the secretion 
of other cytokines, matrix metalloproteinases and macrophage inflammatory protein 
1α, and causes macrophages to express procoagulant tissue factor, and endothelial 
cells to express adhesion molecules E-selectin, vascular cell adhesion molecule 1 
(VCAM1) and intercellular adhesion molecule 1 (ICAM1). This further enhances 
the inflammatory reaction and recruits more lymphocytes and monocytes to the site. 
Anti-CD40L antibody treatment in LDL receptor deficient mice has led to more 
stable plaque by reducing lipid content and the number of macrophages and 
increasing the relative VSMC and collagen content (Schönbeck et al. 2000). Risk 
factors such as hypertension and elevated homocysteine and hormone levels also 
contribute to the development of a fibrous lesion: elevated homocysteine causes 
inhibition of endothelial cell proliferation and stimulates VSMC proliferation and 
collagen production (Tsai et al. 1994, Majors et al. 1997); Angiotensin II, which is a 
component of the renin-angiotensin system that regulates blood pressure, stimulates 
VSMC growth (van Kleef et al. 1996) and the expression of VCAM1 by endothelial 
cells (Pueyo et al. 2000) and the secretion of matrix metalloproteinases (Browatzki 
et al. 2005); oestrogen, on the other hand, is an anti-atherogenic hormone that has a 
beneficial effect on plasma lipoprotein levels, stimulates prostacyclin and nitric 
oxide production thereby enhancing endothelial function. Oestrogen also reduces 
VSMC proliferation (Bush et al. 1998, Dubey et al. 2005, Mendelsohn and Karas 
2005).  
A fibrotic plaque can be stable and asymptomatic for years. Current view on the 
development of ACS is that the unstable complicated atheroma is the most one 
likely to rupture and is the main culprit for events leading to MI. Vulnerable plaques 
exhibit uneven thinning and erosion of the fibrous cap. Thinning occurs most often 
in the shoulder region of the plaque where inflammatory cells infiltrate to the lesion 
(Lee and Libby 1997). This region also has more metalloproteinase expression that 
increases degradation of stabilizing matrix proteins (Shah and Galis 2001). In 
chronic stable ischemia, excess matrix accumulation is the primary mechanism of  
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Figure 1. A schematic illustration of the development of a healthy vessel wall (above) to a 
complicated atherosclerotic lesion (below). During the initial phases of atherosclerosis, 
low-density lipoproteins (LDL) enter the intima and become first minimally modified LDL 
(mmLDL) and then oxidised LDL (oxLDL). Macrophages internalize oxLDL using scavenger 
receptors and present it to T cells with major histocompatibility complex (MHC II) 
receptors. Activated macrophages secrete pro-inflammatory cytokines, proteases, 
procoagulants and pro-apoptotic factors. Accumulation of oxLDL in macrophages 
transforms them into cholesterol-loaded foam cells and during their apoptosis the lipid 
content is relased to the intima. Activated Th1 cells secrete interferon-γ (IFN-γ) and tumor 
necrosis factor alpha (TNF-α) which increase permeability, the propensity for thrombus 
formation and expression of adhesion molecules. Vascular smooth muscle cells migrate and 
profilerate in the lesion and form a fibrous cap over the lipid pool together with 
extracellular matrix proteins. Rupture of the vulnerable plaque leads to the formation of a 
thrombus. 
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occlusion of the atherosclerotic artery lumen. In contrast, it seems that unstable 
lesions may fail to synthesize a sufficient mass of matrix to provide strength to the 
fibrous cap as the number of matrix-producing VSMCs reduces in the fibrotic cap 
(Davies et al. 1993). Increased calcification, neovascularisation and intra-plaque 
haemorrhage may also influence the plaque stability (Fuster et al. 2005, Ijäs et al. 
2007). In addition to inflammatory activity and vascular remodelling, high shear 
stress, which occurs at the throat (minimal luminal diameter) of the plaque, may 
induce endothelial damage and increased platelet deposition, and promote plaque 
rupture (Feldman and Stone 2000). Either subtle erosion or a more severe rupture of 
the endothelial layer exposes the underlying tissue to the blood flow. Contact 
between von Willenbrand factor and collagen and platelet glycoproteins (primary 
haemostasis) launches the clotting reaction and leads to thrombus formation. 
Another mechanism involves circulating factor VII(a) and tissue factor that is 
present on the surfaces of the cells within the plaque. Depending on the severity of 
the wound, fibrinolysis can degrade the thrombus and heal the wound, while 
simultaneously making the plaque more complicated. Alternatively, the forming clot 
is so severe that it causes ACS (Spronk et al. 2004). Figure 1 presents a schematic 
and simplified view of the atherosclerotic lesion development and the major 
participating agents.  
2.1.2 Aetiology of cardiovascular disease 
Cardiovascular disease is a multifactorial disease with both environmental and 
genetic risk factors contributing to its development (Figure 2). The most important 
risk factors are age, male sex, smoking, high blood pressure, a history of MI, type II 
diabetes and elevated blood cholesterol levels (Goldman and Ausiello 2004). 
Metabolic syndrome (MetS), defined as a co-occurrence of at least three out of five 
cardiometabolic risk factors: abdominal obesity, hypertriglyceridemia, low HDL 
cholesterol, high blood pressure, and high fasting glucose, confers a significant 
increase in risk for CVD. Currently several diagnostic criteria can be used and a 
more detailed definition of MetS is available from the World Health Organization 
1999, NCEP 2001, Balkau et al. 2002 and Alberti et al. 2006. Population based 
studies have estimated that individuals with MetS have approximately a two-fold 
increased risk for MI (Smith 2007). In middle-aged Finnish men, MetS is associated 
with a 2-3 -fold increase in risk for CVD (CHD and stroke) and approximately 2-
fold increased risk for total mortality (Lakka et al. 2002). A similar estimate of a 2-
fold increased risk for self-reported CVD has been reported by Ninomiya and 
colleagues (2004) for both sexes in the United States of America. Furthermore, 
independent trait components insulin resistance, hypertriglyceridemia, and 
hypertension are independently and significantly associated with CVD. 
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Primary and secondary prevention in most western countries has achieved a drastic 
decrease in the incidence of first CVD events and the occurrence of recurrent events 
by better treatment (Salomaa et al. 2003) and by being able to reduce cholesterol 
levels, hypertension and the frequency of smoking (Vartiainen et al. 2000). 
Recently, trait components of MetS, increased body weight and type II diabetes, 
have gained importance (Smith 2007). In a recent study of English men, Nanchahal 
and colleagues (2005) reported that among socioeconomic, anthropometric and life-
style risk factors, overweight and obesity now dominate the CHD risk factors in 
men: excess body weight attributed to 47% of high risk CHD (15% 10-year risk) 
and lack of educational qualifications, low income, smoking, and physical inactivity 
accounted jointly for 31%. In Finland as well, obesity is independently from other 
risk factors associated with an increased risk for CHD both in men and in women 
(Jousilahti et al. 1996b). In addition to genetic susceptibility and traditional risk 
factors, health behaviour, such as diet and physical activity, and other environmental 
risk factors, infections and intra-uterine environment modify the risk for CVD (Lusis 
2003). It is important to note that many CVD risk factors also have a genetic 
component (Table 3) and that genes affect also many environmental risk factors. 
The underlying mechanisms by which different risk factors affect the risk for CVD 
may be related directly to the development of atherosclerosis or indirectly by 
Figure 2. Multifactorial genesis of coronary artery disease. Both vascular, 
environmental and genetic risk factors contribute to the disease. 
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affecting the development other risk factors such as insulin resistance or 
hypertension.  
Although the risk for CVD is clearly associated with ethnicity, population studies 
suggest that differences in environmental risk factors largely explain the differences 
in CVD incidence between populations. For example, the incidence is much lower in 
the Japanese compared to the American population, but has increased significantly 
in Japanese individuals who have moved to America and adopted a western life-
style (Robertson et al. 1977). Based on the World Health Organization (WHO) 
MONICA study the differences, however, cannot be fully be explained by 
differences in the known environmental risk factors (Tunstall-Pedoe 2003). 
 
 Table 3. Heritability estimates for cardiovascular disease risk factors. 
Risk factor Heritabilitya 
  Type II diabetes 40–80% 
  Total cholesterol 40–60% 
  Systolic blood pressure 50–70% 
  Diastolic blood pressure 50–65% 
  HDL-cholesterol 45–75% 
  Triglycerides 40–80% 
  Body-mass index 25–60% 
  Lipoprotein-a levels 90% 
  Homocysteine levels 45% 
  Fibrinogen levels 20–50% 
  C-reactive protein  30–40% 
a Modified from Lusis (2003) with heritability estimates also from  
 Austin et al. 2004, Pankow et al. 2001 and Vickers et al. 2002.  
 
S e x u a l  d i m o r p h i s m  i n  t h e  a e t i o l o g y  o f  C V D  
The underlying causes in the different risk for CVD between men and women are 
numerous. The physiological differences are apparent already in childhood. For 
example, the constitution of intimal tissue has been shown to be different between 
male and female children among Ashkenazy children but differences were less 
apparent among those of Bedouin origin (Vlodaver et al. 1969). Also, already in 
early adulthood, differences in the extent of fatty streaks and raised lesions between 
men and women follow the pattern of adults, that is, the abdominal aortas of women 
have more fatty streaks than abdominal aortas of men but they have an equal extent 
of raised lesions, and that the coronary arteries of men have a similar extent of fatty 
streaks as women but they have more raised lesions. (McGill et al. 2000) 
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CVD risk factors are the same for both sexes, but the frequency and relative impact 
differs. For example, it appears that in younger women body-mass index (BMI) does 
not correlate positively with the extent of atherosclerosis as it does in younger men 
(McGill et al. 2000). In women, increased waist/hip ratio (WHR) seems to confer 
increased risk for CVD irrespective of BMI while in men WHR was a significant 
risk factor only among the normal weight individuals (Li et al. 2006). Men have in 
general less favourable CVD risk factor profile than women (Jousilahti et al. 1999). 
The relative increase in risk for CHD per change in risk factor level seems to be 
similar in both sexes, but for women the absolute risk is much lower for any given 
level of a risk factor (Isles et al. 1992). In the Finnish population, the age-related 
increase of CHD incidence was associated with increases in blood pressure, total 
cholesterol, relative body weight and diabetes prevalence to a larger extent in 
women than in men (Jousilahti et al. 1999). Other studies as well have suggested 
that diabetes, hypertriglyceridemia and low levels of HDL cholesterol (HDL-C) 
appear to be stronger risk factors for women (Mosca et al. 1997). On the other hand, 
in age group stratified analysis, the composite risk factor metabolic syndrome seems 
to be a stronger risk factor for CHD in males. For women over 55 years of age and 
men of all ages, MetS confers nearly a 2-fold increased risk for CHD but for women 
less than 55 years of age there is no increase in risk (Tong et al. 2005). 
Sex hormones are the most obvious difference between men and women. Oestrogen 
has several atheroprotective properties presumably contributing largely to the 
observed difference in CVD risk. Jensen and colleagues (1990) studied women 
before and after menopause and observed a significant increase in total cholesterol, 
LDL cholesterol (LDL-C) and triglycerides and a significant decrease in HDL-C 
independent from biological age. These changes towards a more atherogenic lipid 
profile are most likely attributable to the decreased levels of oestrogen. As reviewed 
by Dubey and co-workers (2005), studies on hormone replacement therapy (HRT) in 
post-menopausal women report controversial results for the use of HRT and the risk 
for CVD. It is likely that the timing of the therapy in relation to extent of 
atherosclerosis is crucial: when administered early HRT has several atheroprotective 
effects while the effects can be detrimental in established atherosclerotic disease. 
The use of combined oral contraceptive (including both oestrogen and progestogen) 
is associated with increased risk for CVD but there is less evidence for progestogen 
only contraceptives (The ESHRE Capri Workshop Group 2006). In addition to the 
hormonal factors, the relationship between sociological status and modifiable CVD 
risk factors differ between the sexes (Helmert et al. 1997, Myint et al. 2006). 
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2.1.3 Inflammatory risk factors 
For long, elevated cholesterol levels and the accumulation of lipid in the artery wall 
have been considered the main culprit of cardiovascular disease. In the 1970’s and 
80’s a new theory emerged proposing that growth factors and vascular smooth muscle 
cell proliferation are also involved in the development of atheroma (Ross and Glomset 
1973). Later it was noted that cells of the immune system are widely present in the 
atherosclerotic plaque (Jonasson et al. 1986) and that the disease seems to be driven by 
inflammatory mechanisms. Moreover, total leukocyte count (Yarnell et al. 1991, 
Danesh et al. 2000) and levels of systemic inflammatory mediators interleukin 6 
(Ridker et al. 2000, Tzoulaki et al. 2007), fibrinogen (Danesh et al. 2005), TNF-α 
(Tuomisto et al. 2006), serum amyloid A (SAA) and C-reactive protein (CRP) 
(Danesh et al. 2000) have been shown to predict the onset of CVD.  
Meta-analyses of the association between total leukocyte count, and fibrinogen, 
albumin, SAA and CRP concentrations indicated that in long-term prospective 
studies, for each of the factors, the difference between the highest third and lowest 
third was associated with a 1.5-2.0 times increased risk for CHD (Danesh et al. 
1998, Danesh et al. 2000). Somewhat unexpectedly, of the specific leukocyte types, 
neutrophils and granulocytes, not lymphocytes and monocytes which have been 
shown to contribute to the atherosclerosis development, were associated with 
increased risk for CHD (Wheeler et al. 2004). The association between granulocytes 
and CHD was apparent in both sexes separately, but was independent from CRP 
only in men (Rana et al. 2007). 
The inflammatory mediators IL6, fibrinogen, TNF-α and CRP are acute phase 
proteins that respond to injury. Synthesis of these factors takes place mainly in the 
liver, but recently adipose tissue has emerged as another source of cytokines (Arner 
2007). All of these proteins react differentially in response to infection, injury or 
trauma. For example, the plasma concentration of CRP and serum amyloid A can 
rise 10000-fold while fibrinogen and the total leukocyte count rises 3-fold (Danesh 
et al. 1998, Gruys et al. 2005). While these proteins response rapidly and with a 
wide range of concentration, the long-term circulating concentrations show low 
intra-individual variation (Danesh et al. 2004). Studies on the inflammatory markers 
indicate that, a small increase in the levels of acute phase proteins, also known as 
low-grade inflammation, is associated with elevated risk for CHD. For example, 
based on the distribution of plasma high sensitivity CRP (hsCRP) in most adult 
populations, approximate tertiles <1.0, 1.0-3.0 and >3.0 mg/l have been suggested to 
correspond to low, intermediate and high risk for CHD. Values >10 mg/l are 
associated with an acute infection (Pearson et al. 2003). 
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I n f e c t i o n  a s  a  r i s k  f a c t o r  f o r  C V D  
Seroepidemiological studies have suggested that infections due to several different 
microorganisms are associated with CHD. These studies have identified, among 
others, herpes viruses, Clamydia pneumoniae and Helicobacter pyroli bacteria, and 
dental pathogens within the atherosclerotic lesions. Furthermore, studies on animals 
have shown that infections can initiate atherosclerosis (Alber et al. 2000, Sunnemark 
et al. 2000). In humans, acute respiratory infection has been associated with acute 
myocardial infarction. The hypothesis is that the association between CHD and 
infections is related to immune defence mechanisms, and acute and chronic 
inflammation (Meier et al. 1998, Leinonen and Saikku 2002). Although studies have 
identified individual pathogens within the lesions, antibiotic therapy trials have not 
been successful in preventing CHD or reversing the development of the disease 
(Leinonen and Saikku 2002). Another possible mechanism by which pathogens may 
contribute to the disease is the number of different pathogens (the ‘pathogen burden’ 
-hypothesis). An increasing number of pathogens have been associated with an 
increased risk for MI or death among patients with prevalent coronary artery disease 
both in cross-sectional and prospective studies (Zhu et al. 2000, Zhu et al. 2001). 
Spahr and colleagues (2006) have made a similar observation on the periodontal 
pathogen burden.  
I n f l a m m a t o r y  m e d i a t o r s :  m a r k e r s  o r  m a k e r s  o f  C V D ?  
Inflammatory markers may be either risk factors (directly or indirectly causal to the 
disease) or markers of the risk for CVD. In atherosclerotic disease, they might 
measure other characteristics than the atherosclerotic mass. These include the 
activity of lymphocyte and macrophage populations within plaque or the degree of 
plaque destabilization and ongoing ulceration or thrombosis. On the other hand, they 
may measure the activity of the systemic response to risk factors, such as, diabetes, 
hyperlipidemia, cigarette smoking or obesity (Pearson et al. 2003). There are 
alternative ways in which inflammatory mediators may contribute to the 
development of atherosclerosis. These are: 1) cytokines released from the 
atherosclerotic lesion promote synthesis of CRP and other mediators in the liver, 2) 
metabolic changes due to other reasons than atherosclerosis causes increased 
synthesis of these factors both in the liver and in the plaque and there is no direct 
causal relationship between the factors and the atherosclerotic disease, 3) metabolic 
changes induces synthesis of these factors in the liver and they subsequently 
promote atherosclerosis (Nilsson 2005). In the case of CRP there is some evidence 
of causality: in vitro studies have demonstrated that CRP mediates endothelial 
apoptosis and secretion of matrix metalloproteinase-9 by human mononuclear cells 
(Nabata et al. 2007), and that it regulates VCAM1 expression in bovine vascular 
endothelial cells (Kawanami et al. 2006). On the other hand, a study on the 
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overexpression of CRP in transgenic mice suggests that CRP does not contribute to 
the disease and that it might simply be a marker after all (Reifenberg et al. 2005).  
Similarly, there is evidence that IL6 is expressed in the human atherosclerotic 
plaque (Schieffer et al. 2000), and that IL6 mediates atherosclerotic progression by 
stimulating macrophages to secrete monocyte chemotactic protein 1 (Biswas et al. 
1998), and by promoting endothelial cells to express adhesion molecules and to 
secrete cytokines in vitro (Romano et al. 1997). In a study by Schieffer and 
colleagues (2004), ApoE and IL6 deficient double-knockdown mice showed 
evidence of increased lesion formation but decreased recruitment of macrophages 
and lymphocytes. The level of anti-inflammatory cytokine interleukin 10 (IL10) was 
reduced in these animals, and they had hypercholesterolemic lipid profiles. 
Supraphysiological concentrations of IL6 have been shown to enhance fatty lesion 
formation in ApoE deficient mice, but not in atherosclerosis resistant mice (Huber et 
al. 1999). Together these studies suggest that IL6 contributes directly in many 
aspects of atherosclerosis progression in atherosclerosis-prone circumstances and 
that the balance between IL6 and IL10 is crucial for lipid homeostasis and plaque 
formation. 
M o u s e  m o d e l s  o f  a t h e r o s c l e r o s i s  -  c o n t r i b u t i o n  o f  
i n f l a m m a t i o n  
Genetically modified mouse models have increased our knowledge of the 
contribution of inflammatory mediators in the development of atherosclerotic 
plaque. For example, the role of T-lymphocytes is exemplified by a study, which 
showed that severe combined immunodeficient mice on an Apoe-/- background had 
smaller lesions than mice injected with CD4+ T-lymphocytes (Zhou et al. 2000). 
Lymphotoxin alpha (LTA), which has been associated with MI in a Japanese study, 
has been shown to be expressed in early lesions and LTA-/- knockout animals showed 
smaller lesions (Schreyer et al. 2002). Human CRP transgenic mice that were LDL 
receptor (LDLR) null and expressed exclusively ApoB-100 (Ldlr-/- Apob100/100), on 
the other hand, showed decreased lesion development compared to their control 
littermates. This finding supports the atheroprotective role of CRP adding another 
piece to the puzzle of the role of CRP in this disease (Kovacs et al. 2007). 
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2.2 Genetic epidemiology of complex diseases 
2.2.1 DNA, genes and the human genome 
Every human nucleated cell contains two genomes: a mitochondrial genome of 
roughly 16570 base pairs and a nuclear genome of approximately 3 billion base 
pairs of DNA. The nuclear genome is organized into 22 autosomal chromosomes 
and sex-determining X and Y -chromosomes. Anderson and colleagues (1981) 
published the sequence of the mitochondrial genome in the year 1981. Massive 
academic and private efforts finished the first draft of the human nuclear 
euchromatic genome in 2001 (Lander et al. 2001, Venter et al. 2001) and three years 
later the International Human Genome Sequencing Consortium (2004) finished 
filling the remaining gaps covering approximately 99% of the euchromatic genome.  
In the simplest view, genes are the functional units of the genome that encode 
proteins. Currently the estimate of the number of protein-coding genes in the human 
genome is ~21800 (www.ensembl.org, database build 47.36i) but the number varies 
largely between individuals According to Nozawa and co-workers (2007) 
approximately 14% of the human genes are polymorphic with respect to copy 
number. The organization of the human genome is, however, much more complex as 
described by Gerstein and co-workers (2007). In addition to protein-coding genes, 
the genomic sequence contains information for other functional elements such as 
non-coding ribonucleic acid (RNA) molecules. Moreover, from the same sequence 
of a gene there can be alternatively spliced messenger RNAs (mRNA), the reading 
frame of mRNA can be changed to produce an alternative product, and the RNA 
molecule can be edited post-transcriptionally. Furthermore, the traditional view of 
alternating exons and introns of a gene has been revised. The same genomic 
sequence can code for a different product from both chains, there can be a coding 
sequence for another gene within an intron of a gene, and regulatory elements of 
both can be intertwined. All these phenomena regulate how the information in the 
genome is translated into the function of the cell and acknowledgment of these facts 
makes the definition of a gene complicated. In addition, interpreting and predicting 
the function and consequences of variants in the noncoding region is difficult and 
less well understood than the effect coding variants have on protein function 
(Glazier et al. 2002). As a result, interpretation of findings from complex disease 
mapping can be very challenging.  
V a r i a t i o n  i n  t h e  g e n o m e  
It has been estimated that every nucleotide in human genome differs between some 
individuals in the world if the change is compatible with life. In a recent study Levy 
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and co-workers (2007) estimated that any given individual differs genetically by 0.1-
0.5% from other humans. This fraction of sequence dissimilarity contains several 
types of variation and polymorphisms, polymorphisms being variations that are not 
sporadic rare mutations. Different kinds of variations and polymorphisms constitute 
the basis of human inherited diseases. The majority of this variation is single 
nucleotide polymorphisms (SNP); the current catalogue includes approximately 6.2 
million validated SNPs (www.ncbi.nlm.nih.gov/SNP, Genome build 36.2, dbSNP 
build 128). Since our knowledge of the human sequence is currently based on only a 
few sequenced individuals, and hence only from a small amount of diversity, this 
number is most likely an underestimate. According to the neutral theory of mutation 
(mutation is selectively neutral), a SNP with >1% frequency occurs in every ~300bp 
of the 3.2 billion base pair genome adding up to roughly 11 million SNPs in total 
(Kruglyak and Nickerson 2001). SNPs occur everywhere in the genome, but are 
more abundant in intragenic non-coding regions and in regions immediately around 
coding regions than in exons and introns of the genes where they are more likely to 
have a deleterious effect on the gene product (Salisbury et al. 2003). 
Other types of variation include repetitive elements of various sizes: insertions, 
deletions, inversions, duplications and translocations of DNA sequences. Recently 
several investigators have identified submicroscopic copy-number differences (also 
known as copy-number variants, CNVs) of various types ranging from kilobases to 
megabases in size. These CNV regions covered 12% of the human genome in a 
study of 270 individuals from four populations and included genes, disease loci, 
functional elements and segmental duplications. For example, one of the candidate 
genes of this study (II), selenoprotein S is located in a CNV that is approximately 
5% frequent in Caucasians. CNVs have been shown to affect phenotypic variation 
by influencing gene expression and gene dosage (Redon et al. 2006) and analyzing 
them parallel to other variants will most probably give more insight into the genetic 
background of complex human traits. 
P a t t e r n s  o f  l i n k a g e  d i s e q u i l i b r i u m  
Humans inherit one copy of the nuclear genome from both parents. During meiosis 
homologous chromosomes from both gametes align and are independently assorted 
to the offspring. Two loci in the same chromosome are non-independently inherited 
unless a recombination event between the loci breaks the link. The result, non-
random association of alleles within a chromosome is called linkage disequilibrium 
(LD) and it arises because the variants share a joint population ancestry (Figure 3). 
There are several measures for quantifying LD. Of these Lewontin’s D, absolute 
value of D’ and r2 are the most commonly used. The correlation coefficient r2 
depends on the allele frequency and intuitively tells us how much information one 
locus provides from the other. (Ardlie et al. 2002)  
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The extent and patterns of LD across the human genome have been a focus of wide 
interest. In addition to recombination and mutation, different evolutionary events 
modify the extent and distribution of LD. Genetic drift (the random distribution of 
alleles to the finite number of offspring), and bottlenecks (the random sampling of 
gametes during restriction in population size) are manifestations of chance acting on 
the constitution of the human gene pool. Rapid expansion of population size after a 
bottleneck reduces genetic drift and decreases LD while admixture and migration 
can increase LD momentarily due to allele frequency differences in the populations. 
This spurious LD between unlinked markers decreases rapidly in subsequent 
generations. Natural selection can modify LD when a larger flanking region of a 
favourable allele also increases in frequency or when a deleterious allele disappears 
altogether reducing surrounding variability thus increasing LD. (Ardlie et al. 2002) 
 
 
Several studies have investigated the properties of LD in smaller chromosomal 
regions and in the genome as a whole. Although the studies have varied immensely 
in regard to size, population, marker type and density as well as measures of LD 
used, it has become clear that both the quantity and structure of LD varies between 
populations and between genomic regions (Ardlie et al. 2002). The average length of 
useful LD in European populations ranges from 6 kb in low LD areas to more than 
20 kb in high LD areas and is markedly less in African populations (Reich et al. 
Figure 3. The decay of linkage disequilibrium (LD). The shared chromosomal segment 
around the mutation in the founder chromosome shortens due to recombination events in 
subsequent generations (N=number of generations). After 15 generations, only a short 
segment is preserved and only marker (M) 3 remains in LD with the mutation. 
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2001, Shifman et al. 2003). Studies focusing on long distances have generally 
reported excess LD whilst studies in shorter segments show less than expected LD 
across the distance (Pritchard and Przeworski 2001). Demographic features such as a 
constant size of small population or small sub-isolates seem to lead to extended LD 
(Kaessmann et al. 2002, Varilo et al. 2003). As a whole, isolated populations exhibit 
higher overall levels of LD than outbred populations (Service et al. 2006). 
Analysis on the LD structure has led to the understanding that in the human genome 
regions of high LD are punctuated with regions of increased recombination (Daly et 
al. 2001, Jeffreys et al. 2001). Though the estimates of LD in some of these studies 
may be biased upwards due to limited number of chromosomes (Terwilliger et al. 
2002) and thus leads to an optimistic view of the block structure, regions of high LD 
are present in the genome in all populations. The block structure, however, differs 
markedly between populations and even within geographic regions (Gu et al. 2007). 
Haplotype diversity between populations is great and generally, in a given locus, 
only a few common haplotypes are frequent in all populations worldwide (Kidd et 
al. 2004).  
2.2.2 Genome-wide statistical methods for identifying genes 
underlying complex diseases 
G e n e t i c  m a r k e r s  
In principle, the search for susceptibility genes or loci for common diseases can 
utilize all types of genetic variation as genetic markers. The feasibility and 
affordability of the genotyping together with the information content of the markers 
define the design of a large-scale genetic study. Short tandem repeats, also know as 
microsatellites, have been the first to be put to use in large-scale genotyping efforts. 
Polymerase chain reaction (PCR), that can amplify many markers simultaneously, 
facilitates reduction in the cost and use of DNA material. Microsatellites have 
multiple alleles, higher mutation frequency than SNPs and thus have high 
information content (Hearne et al. 1992, Kruglyak 1997). Marker information 
content affects detectable LD and thus restricts the choice of analysis method and 
affects the power of the study (Varilo et al. 2003). 
SNP markers are most often bi-allelic and occur more frequently in the genome than 
microsatellites. Recent technological advances have made it possible to analyse 
thousands of SNPs at a relatively affordable price and with modest consumption of 
DNA sample (Syvänen 2005). SNP markers have lower information content than 
microsatellites but are more stable and located more often near and within genes. 
Although many more SNPs than microsatellites are required to reach a similar 
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genetic density and information content, with the current genotyping technologies 
this has become feasible and allows for multiple uses of SNPs in genetic analyses 
(Kruglyak 1997, Steemers and Gunderson 2007).  
F a m i l y - b a s e d  l i n k a g e  a n a l y s i s  
Genetic mapping aims to identify the chromosomal regions where the disease-
associated genes are located. This can be achieved with positional cloning using 
multi-generational families segregating the disease and genome-wide marker sets. 
Linkage analysis looks for chromosomal regions that are linked with the disease i.e. 
segregate together with it in the family. Statistical methods, which calculate the 
probabilities of the observed recombination between two adjacent markers given the 
genetic distance, use information of the family or pedigree structure to aid the 
analysis. Parametric methods rely on a priori information of the recombination 
fraction along the genetic map, mode of inheritance, penetrance, phenocopy rate, 
marker allele frequencies and disease allele frequency (Terwilliger and Göring 
2000). In the case of rare monogenic diseases these parameters have been relatively 
easy to define correctly and they have aided mapping of several disease genes 
(Collins 1995, Peltonen et al. 1999). In complex disease mapping, these parameters 
are difficult, if not impossible, to define reliably beforehand. Non-parametric 
methods, such as the affected sib pair analysis, investigate in affected individuals the 
proportion of allele sharing, which is expected to be greater than random Mendelian 
segregation in a disease-linked locus (Terwilliger and Göring 2000). 
A s s o c i a t i o n  a n a l y s i s  
Genome-wide genetic association studies (GWA) for complex diseases are likely to 
be more powerful than linkage studies in identifying several predisposing genes with 
small effects (Risch and Merikangas 1996). The analysis method can be used for 
several types of study samples and any number of markers. The most common study 
sample is population based case-control analysis in affected and unaffected, so 
called control, individuals. Other types of study designs include a population based 
case-cohort analysis and family based analysis, where it is possible to analyze both 
linkage and association separately and together (Terwilliger and Ott 1992). 
Association study compares whether the allele frequency of the genetic marker is 
significantly different in the affected and unaffected groups.  
Any type of genetic markers can be used for association analysis. Direct association 
mapping aims to select the disease-causing variant, e.g. a known coding region 
variant or a variant from a known regulatory region, for the analysis, whereas 
indirect study design relies on significant LD between the typed marker and the 
putative functional variant (Figure 4). However, since indirect association analysis 
can be thought to observe the haplotype background of a variant, which has been 
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introduced several generations ago into the gene pool in individuals who are 
currently identical-by-decent for the variant, are SNPs with lower mutation rate 
better for this analysis than microsatellites (Kruglyak 1997, Terwilliger and Göring 
2000). 
 
 
As described by Manolio and colleagues (2006), association study designs are either 
retrospective or prospective. The most common has been retrospective design, in 
which the researchers collect information about the predisposing environmental risk 
factors after the affected and unaffected study subjects have been identified. 
Although this design is economically the most feasible, there is a possibility for bias 
between cases and controls in assessment of past exposure to risk factors. Recall 
bias may occur if cases and their family members remember, influenced by their 
current health status, potential harmful exposure more often than the controls. In 
prospective design, the study collects information about the risk factors at the 
baseline and identifies, through a follow-up, the individuals who are affected. 
Prospective cohort study also provides us with unbiased risk estimates, whereas in 
case-control studies the odds ratio approximates the relative risk only if the 
probability of getting the disease is small (Zondervan and Cardon 2004). 
Figure 4. Indirect and direct association testing. A test between 
the causal variant (full circle) and the disease phenotype is a test of 
direct association whereas a test between a surrogate variant (open 
circle) and the phenotype is indirect. Indirect association is possible 
because of linkage disequilibrium (LD) between the variants. 
Gene Haplotype
Disease phenotype
LD
LD
Direct association
Indirect association
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Case-control studies identify cases often through clinics and have the advantage of 
collecting cases of rare diseases and mild conditions. For a cohort study to identify 
as many cases, it would have to be very large and utilize a very powerful follow-up 
method, something that is often impossible to achieve. The advantage of a case-
cohort study is that it can identify several types of diseases and use the same control 
cohort (a subcohort sampled from the cohort) and exposure information for all end-
points thus reducing the cost of genotyping and phenotyping (Prentice 1986, 
Zondervan and Cardon 2004, Manolio et al. 2006). The principles of both designs 
are described in Figure 5 and discussed further in 2.2.5.  
A l l e l e  s p e c t r u m  o f  c o m p l e x  d i s e a s e s  
The nature of allelic variants underlying complex diseases has been much debated 
over the recent years. Multifactorial diseases, by definition, are influenced by 
incompletely penetrant variants. Furthermore, it is unlikely that a variant would be 
both common and confer a high risk since it would have to be the principal 
contributor to the overall prevalence. In addition, it can be assumed that common 
deleterious variants with large effects would not be the cause of common diseases 
since they would have been selected against in the course of evolution (Zondervan 
and Cardon 2004). Linkage studies have generally failed to detect variants with 
large effects conferring risk for complex diseases. Many researchers have thus 
suggested that one, or small number of, common variants with small effects in given 
genes would be the cause of common diseases (Lander 1996, Risch and Merikangas 
1996, Collins et al. 1997). In the case of late onset diseases, such as cardiovascular 
disease, the disease is not likely to affect the reproductive fitness of the individual, 
and is thought to have developed without selective pressure on the genetic variants. 
As a result, the variants underlying CVD may have evolved neutrally and exhibit a 
wide range of frequencies, allelic heterogeneity and epistasis (Weiss and Terwilliger 
2000). Alternatively, variants that are now disease-predisposing and common might 
have been advantageous and not under negative selection in the past (i.e. the ‘thrifty-
gene’ hypothesis) (Neel 1962). 
Although there is empirical (Lohmueller et al. 2003) and theoretical (Reich and 
Lander 2001, Peng and Kimmel 2007) evidence that the common disease, common 
variant (CDCV) hypothesis holds true, opposing arguments have also been 
presented. It has been suggested that, since environmental factors are so important in 
the development of complex disease, individual allelic variants must confer low 
attributable risk and be rare (Weiss and Terwilliger 2000). Particularly in late-onset 
diseases, a theoretical modelling proposes that when one assumes neutral selection 
in constant size population, common variants would contribute little to the genetic 
variance since they would be close to fixation (Pritchard 2001). Furthermore, 
empirical evidence from late-onset Mendelian disorders suggests that causal genetic  
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variants that have failed to influence fitness have a broad allelic diversity (Wright 
and Hastie 2001). Currently, we do not have enough empirical evidence to know 
which model describes the allele spectrum of complex disease most precisely and 
most likely the spectrum includes both common and rare variants with allelic and 
locus heterogeneity. 
Figure 5. Case-control and case-cohort study designs. At the beginning of the study, case-
control studies identify affecteds and unaffecteds and then proceed to assess their past 
exposure to risk factors. In a case-cohort study, the study begins by selecting the 
representative cohort from the base population, and assessing their exposure. During the 
follow-up individuals who become affected are identified. A random subcohort drawn from 
the original cohort represents the controls in the survival analysis.
Time
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exposure
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T h e  h a p l o t y p e  m a p  o f  t h e  h u m a n  g e n o m e  
The hypothesis, that each disease-causing locus harbours only one or a few 
causative variants and that these variants would be common, forms the foundation of 
a project HapMap that aims to construct a haplotype map of the human genome. The 
HapMap is a publicly available resource of haplotype information across the 
genome based on common SNPs. The aim is to enable researchers to study the local 
structure of LD and select variants from haplotype blocks to represent haplotype 
variation within their region of interest, or the genome as a whole, and thus reduce 
the number of variants in the study (The International HapMap Consortium 2003).  
Methods for selecting the representing variants are available and have been 
demonstrated to describe the underlying haplotype diversity. Alternative methods 
encompass selecting haplotype tagging SNPs (htSNP) to detect common haplotypes, 
selecting htSNPs that define haplotype blocks, and selecting tagSNPs that describe all 
common variation within the gene with a specified correlation threshold using r2 as the 
metric (Johnson et al. 2001, Stram et al. 2003, Zhang and Jin 2003, Carlson et al. 
2004). TagSNPs can generally be fairly well transferred between populations, 
including population isolates, such as Finland (Willer et al. 2006). However, when Gu 
and colleagues (2007) selected htSNPs from later populations along the out-of-Africa 
path: Africa, southwest Asia, Europe and the Americas or east Asia, they did not 
capture the haplotype diversity in the earlier populations as precisely as did a selection 
made vice versa. This observation agrees with the evolutional hypothesis that older 
mutations will be more common and have a shorter shared haplotype around them, 
thus having less correlation with surrounding variants (Kidd et al. 2004). 
According to the CDCV and HapMap hypotheses, it is possible to use indirect 
association mapping to localize disease-predisposing genes for complex diseases 
(Pritchard and Cox 2002). However, some researchers point out that some of the 
underlying assumptions of the HapMap project may be questionable. Allelic 
heterogeneity reduces the power of the study, as do overestimates of the amount of 
LD and similarity of the structure of LD across populations (Weiss and Terwilliger 
2000, Terwilliger et al. 2002, Weiss and Clark 2002). In addition, there is doubt 
whether it can be statistically possible to detect indirect association even in the case 
of perfect LD (Terwilliger and Hiekkalinna 2006). Furthermore, the extent of LD 
around common variants is usually less than around rare variants, since evolution 
has had more time to increase haplotype diversity (Jorde 1995, Kruglyak 1999). 
Studies in isolated populations and especially in sub-populations with recent 
demographic events that have reduced allelic heterogeneity and increased the extent 
of LD may be better equipped to circumvent some of these problems (Kaessmann et 
al. 2002, Varilo and Peltonen 2004). The greater extent and homogeneity in LD can 
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be also achieved by adopting analysis in disease-ascertained pedigrees in isolates 
(Varilo et al. 2000).  
Despite all the doubts listed above, many recent studies have demonstrated that the 
tagSNP approach can be used for genome-wide association studies. The ~1.3 million 
SNPs included in the HapMap Phase I have been successfully used in replicating 
previous associations and identifying new candidate loci and genes for common 
diseases: type I diabetes (Hakonarson et al. 2007), type II diabetes (Sladek et al. 
2007, Steinthorsdottir et al. 2007), and myocardial infarction (Helgadottir et al. 
2007) to name a few. The HapMap Phase II launched in 2007 added a further 2.1 
million SNPs and has the average spacing of one SNP per kilobase. It now includes 
more rare variants than the previous release, and with the increased density, allows 
for more detailed definition of recombination hot spots and haplotype blocks (The 
International HapMap Consortium 2007). The Wellcome Trust Case Control 
Consortium GWA studies have identified several new candidate genes and loci for 
common traits and diseases using an Affymetrix 500K genotyping platform that 
covers ~70% of the Phase II SNPs (The Wellcome Trust Case Control Consortium 
2007). It seems now plausible that GWA studies can identify common variants 
conferring risk for common traits and diseases, and that the tagSNP approach can be 
utilized in this type of study design. However, the effect size of identified variants is 
most often very small and thus their clinical usability remains yet to be determined. 
Most of the findings are, nevertheless, pathobiologically very interesting. 
2.2.3 Candidate gene -approach 
While genome-wide studies aim to locate the genomic region predisposing to the 
disease, candidate gene approach starts with a priori hypothesis of the role of the gene 
in the aetiology of the disease. The gene can be a positional candidate from previous 
genome-wide studies, or it can be selected based on studies in model organisms, or 
biological hypothesis and known functions of the gene. In contrast with genome-wide 
studies, candidate gene studies often select variants with predicted or known 
functional role affecting protein structure or folding, splicing of the gene, regulatory 
elements, or gene expression as candidates for direct association testing. The same LD 
based selection algorithms for indirect association studies are applicable to these 
studies as for the genome-wide approach (Tabor et al. 2002). Moreover, since the 
region of interest is generally of manageable size, in-depth re-sequencing can be used 
to discover a full pattern of variation within the gene, and densely spaced variants can 
be included in the study. This increases confidence that a full spectrum of variation has 
been analysed and the null hypothesis of no genetic association can be accepted or 
rejected with greater certainty (Cordell and Clayton 2005).  
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2.2.4 Evaluation of the statistical significance of association studies 
The literature of genetic association studies, including CVD, is full with initial 
positive findings followed by lack of replication or inconsistencies in the findings 
(Ioannidis et al. 2001, Ntzani et al. 2007). There are many reasons for this 
phenomenon (Figure 6). First, the lack of replication may be entirely correct and the 
initial finding is a false-positive association. The amount of false-positive results in 
the literature relates mostly to the power of the studies. Power is defined by the 
probability of not finding an association when a true one exists (i.e. 1-type II error 
rate). The prior probability of true association, the size of the study, the effect size of 
the variant, as well as, the required level of statistical significance (i.e. type I error 
rate, α) has an influence on the power (Colhoun et al. 2003, Livingston and Cassidy 
2005). In addition, problems in the power to detect disease association arise when 
the study uses indirect association and the LD is incomplete, and most importantly, 
the marker allele frequency differs from the disease allele frequency (Müller-
Myhsok and Abel 1997, Zondervan and Cardon 2004). The inability to exclude 
chance findings at the desired level of statistical significance relates both to the 
power of the study and to the number of analysed variants, i.e. multiple testing 
problem. Most studies have investigated too few individuals to face the multiple 
testing problem especially in the context of small effect sizes of variants 
predisposing to complex diseases. Estimates for the necessary number of individuals 
have been presented for various study designs and numbers of markers (Risch and 
Merikangas 1996, Risch 2000). In principle, the number of individuals increases n-
fold if the required level of statistical significance reduces n powers of 10 (Colhoun 
et al. 2003).  
Several methods to correct statistically for the multiple comparisons are available. 
Bonferroni correction straightforwardly compensates for n independent tests by 
setting the significance threshold at α/n. It is generally agreed that the Bonferroni 
correction is too conservative for studies including markers in LD and correlated 
phenotypes (Balding 2006). A supplementary method called SNPSpD can be used to 
estimate the effective number of markers and adjust the significance threshold 
accordingly. The method accounts for the non-independence by using spectral 
decomposition (Nyholt 2004). An alternative approach is false discovery rate (FDR), 
which monitors for the proportion of false positive results among all positives 
(Benjamini and Hochberg 1995). A practical option is to perform permutation 
testing to obtain a false-positive rate by generating several data sets by breaking the 
link between genotype data and phenotype data (Churchill and Doerge 1994).  
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False-positive findings may also arise due to manipulation of analysis strategies. As 
an example, studies occasionally extend the original analysis plan during the 
analysis process, and in the end, report findings only from subgroup analysis, such 
as, sex, age and specific subcategory of phenotypes. Sometimes these exhibit the 
only signs of association and should be viewed with caution (Colhoun et al. 2003). 
However, with strong biological hypothesis – e.g. different aetiology of a disease in 
men and women – subgroup analyses are an important part of the research but 
should be incorporated in the analysis strategy from the very beginning (Pilote et al. 
2007). 
Inadequate power leads to the second main form of lack of replication in which a 
correct report of a true association fails to be replicated in an underpowered follow-
up study. In addition, heterogeneity in study designs is one source of inconsistency 
in association reports. Differences in population stratification, selection and 
misclassification of cases and analysis of effect modification may lead to substantial 
differences between studies (Manly 2005). Heterogeneity in genetic or 
Figure 6. The lack of reproducibility in genetic association studies. 
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environmental background may lead to the third major form of unreproducibility 
where a true association in one population may not necessarily be true in a second.  
The power of a study can be increased by increasing the sample size. Since 
increasing the number of individuals in the study is expensive and sometimes 
unfeasible, a multi-stage approach has been proposed especially for large-scale 
genotyping efforts. In this design, interesting findings with less stringent levels of α 
in the initial step are replicated in following independent study samples while 
simultaneously increasing the level of statistical significance (van den Oord and 
Sullivan 2003, Hirschhorn and Daly 2005). Alternatively the power to detect an 
association can be increased by enriching the genetic component in the study 
sample. This leads to increased prior probability of observing a genetic effect 
(Antoniou and Easton 2003, Terwilliger and Weiss 2003).  
2.2.5 Study populations, subjects and biological samples 
G e n e t i c  i s o l a t e s  a n d  p e r s p e c t i v e  f r o m  F i n l a n d  
The use of isolated founder populations, such as, Finland, Iceland, Sardinia, the 
Bedouines, the Canadian Hutterites, the Old Order Amish, the North American 
Mennonites, and the Ashkenazi Jews has aided identification of monogenic forms of 
diseases. In these populations, a small number of founder chromosomes have 
introduced the disease allele into the population and the extended LD around the 
rare mutation is still present today. Relative isolation because of cultural or 
geographical or both factors has limited gene flow from other populations. In 
addition, bottlenecks, genetic drift, rapid expansion and formation of internal 
isolates have modified the gene pool leading to reduced genetic diversity and 
enrichment of some alleles (Peltonen et al. 1999, Peltonen et al. 2000). The success 
for mapping complex diseases has been more limited, although some examples 
exist. Linkage analysis followed by association in samples from North-American 
Mennonites has identified the endothelin B receptor as a candidate for Hirschsprung 
disease (Puffenberger et al. 1994a, Puffenberger et al. 1994b). Similarly, linkage 
analysis in one Bedouin extended pedigree identified the chromosomal region of 
connexin 26 in relation to hereditary nonsyndromic sensorineural deafness (Guilford 
et al. 1994, Kelsell et al. 1997). 
Linkage disequilibrium mapping in isolates has been less successful for complex 
diseases, although a few recent examples exist of new putative loci for type II 
diabetes, Parkinson’s disease, atrial fibrillation and exfoliation glaucoma from 
Finland, Iceland and the Netherlands (Bertoli-Avella et al. 2006, Gudbjartsson et al. 
2007, Helgadottir et al. 2007, Scott et al. 2007, Thorleifsson et al. 2007). Assuming 
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CDCV to be the underlying model, the outcome of these studies depends largely on 
the extent of LD around common variants. Even if the number of founders is 
relatively small, common alleles have entered the gene pool several times after the 
origin of the isolate and the shared haplotype around the alleles has become 
indistinguishable from the ancestral haplotypes (Kruglyak 1999). Nevertheless, 
isolated populations may aid in identification of complex disease genes in other 
ways. First, fewer predisposing alleles are likely to contribute to the diseases by 
virtue of reduced genetic and allelic heterogeneity (Collins 1995). Second, cultural 
and environmental homogeneity, and standardized and equally available health care 
reduce phenotypic and etiological variability and diagnostic misclassification, and 
third, in some of the isolates genealogical records allow for accurate construction of 
large pedigrees over several generations (Peltonen et al. 2000). Therefore, initial 
localization of disease-predisposing genes or loci might be somewhat easier in 
isolated than in outbred populations. Identification of the causative variant or fine 
mapping could thereafter utilize, for example, African populations with less LD 
(Reich et al. 2001).  
S e l e c t i o n  o f  s t u d y  s u b j e c t s  i n  p o p u l a t i o n - b a s e d  s t u d i e s   
The selection of subjects is crucial for the success and validity of any genetic 
association study. Genetic epidemiology is as at risk to different kind of bias as is 
traditional epidemiology. In addition to bias related to collection of exposure 
information, several type of selection bias can affect the results (Table 4).  
In case-control studies, the selected subjects should all represent the same 
underlying study base. The same study base is inherent to case-cohort studies. If 
cases are identified as patients of a particular hospital, then the catchment population 
for controls are the individuals in the same hospital district and include all 
individuals who are at risk for developing the disease (Miettinen 1985). In case-
control studies, the selection of controls is even more important than the selection of 
cases. In order to reduce false positive findings and to assist detection of true 
findings, the controls should match the cases by strong confounders (e.g. sex, age, 
ethnicity) affecting the disease aetiology. However, matching by an intermediate 
phenotype or a factor in a causal pathway between exposure and disease can lead to 
overmatching and bias the results (Wacholder et al. 1992). In addition, methods such 
as selection of hypernormal controls (i.e. old individuals who have not developed 
the disease) or the use of population controls representative of the population from 
which the cases originated have been proposed (Hattersley and McCarthy 2005). 
Sampling from a homogenous population, such as a population isolate, reduces 
heterogeneity among lifestyle, environmental and genetic factors in both cases and 
controls and reduces differences in unobserved putative risk factors between these 
groups (Peltonen et al. 2000). 
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Selection of subjects 
Detection signal (unmasking) bias 
An exposure may become a suspect if it causes symptoms that are unrelated to the disease and this 
precipitates a search for the disease.  
Diagnosis bias  
Information of the current exposure to a know risk factor may influence the thoroughness of the 
diagnostic procedure or affect the intensity of the outcome. 
Drop-out bias 
Drop-out bias affects cohort studies where individuals may be lost during the follow-up due to different 
reasons related or unrelated to the disease in question. 
Healthy worker effect 
Members of a group, e.g. employed, athletes etc., may have a significantly different degree of health 
compared to the general population. 
Non-response bias 
The participation rate of affected and unaffected individuals may be different and this may or may not 
be related to the exposures and outcomes in the two groups.  
Prevalence-incidence or survival bias  
The study misses all fatal and silent events and short episodes in cases where evidence of exposure 
disappears after disease onset. 
Referral or admission rate bias  
This bias relates to clinical setting, where the inclusion probability might differ between cases and 
controls depending on the availability of advanced care, burden of symptoms or popularity of disorders.  
Surveillance bias 
Individuals who are provided with routine medical surveillance and have a mild outcome of the disease 
are more likely to be included in the study than individuals without routine surveillance. 
Information on exposures 
Recall bias 
Patients and their family members may search their memory more intensely and more accurately for 
exposures for putative causes of the disease than unaffected individuals. 
Family information bias 
Information of the exposure or illness in the family may be readily more available to affected 
individuals or may be directed to these individuals more than to unaffecteds.  
Exposure suspicion bias 
The putative cause of the disease may be more thoroughly looked for in affected individuals. 
From Sackett (1979) and Manolio (2006). 
 
Table 4. Some sources of bias in genetic epidemiology.
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C o n s i d e r a t i o n s  o n  t h e  q u a n t i t y  a n d  q u a l i t y  o f  
D N A  s a m p l e s  
In order to be successful, a genetic epidemiological study needs to follow several 
stringent quality control criteria, both in collection and in analysis of biological 
samples (Altshuler and Daly 2007). Recently the NCI-NHGRI workgroup on 
replication in association studies (2007) published guidelines for a good initial 
association study as well as a valid replication study. In their proposition, they 
outlined that a study should report the exclusion reasons due to DNA sample 
characteristics, success rate for DNA acquisition and extraction, and comparisons of 
phenotypic characteristics according to sample availability.  
Selection bias (Cardon and Bell 2001) due to sample availability may lead to 
differences in allele frequencies if the rate of dropout is different among cases and 
controls or if the underlying cause of dropout is associated with the disease. Apart 
from differences in willingness to donate a DNA sample and possible difficulties in 
obtaining the sample, for example, from the elderly or small children, the factors 
affecting the availability of DNA sample usually relate to the success of the 
extraction procedure. Several extraction methods are available for different types of 
source tissues (Vandenplas et al. 1984, Miller et al. 1988, Yoza et al. 2002) and SNP 
genotyping accuracy is similar in DNA samples extracted from different tissues 
types (Montgomery et al. 2005). The most commonly used tissue in large-scale 
genetic epidemiological studies has been whole blood, but non-invasive methods 
such as buccal swaps and mouthwashes are becoming more common. The amount of 
available DNA ranges from tens of micrograms per buccal cell sample to hundreds 
of micrograms from 10 ml of peripheral whole blood sample (Steinberg et al. 2002).  
Storage time and temperature of the sample prior to extraction affects the quantity of 
DNA. Freezing reduces the yield in whole blood samples by approximately 25-50% 
(Madisen et al. 1987, Feigelson et al. 2001, Nederhand et al. 2003). The studies on 
the quality of the DNA are more conflicting: in some studies prolonged storage or 
temperatures other than room temperature did not affect the integrity of DNA 
measured as visual inspection of degradation on agarose gel (Lahiri and Schnabel 
1993, Visvikis et al. 1998), whereas other studies have observed degradation (Farkas 
et al. 1996) and increased protein contamination (Nederhand et al. 2003). In addition 
to these technical aspects, the age of the donor correlates negatively with the DNA 
yield from whole blood samples. This is most likely related to the age-associated 
decrease in leukocyte count (Erkeller-Yuksel et al. 1992, Richardson et al. 2006). 
Whole genome amplification (WGA) methods can resolve the problem of low DNA 
amounts in some samples (Silander et al. 2005). Methods, such as, degenerate 
oligonucleotide-primed PCR, primer extension preamplification, and multiply-primed 
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rolling circle amplification (MPRCA) are available, but they are still quite expensive 
and laborious to use (Hawkins et al. 2002). In general, MPRCA phi polymerase based 
methods amplify the genome without great regional or sequence bias and are suitable 
for samples with very low DNA yield. Pooling two amplifications increases 
genotyping accuracy even further (Dean et al. 2002). Both Illumina and Affymetrix 
whole genome genotyping platforms can use WGA samples from various source 
tissues with acceptable genotyping accuracy but with lower call rates (Tzvetkov et al. 
2005, Paynter et al. 2006, Berthier-Schaad et al. 2007).  
2.3 Genetics of cardiovascular disease 
2.3.1 Genetic component 
It has been known for years that cardiovascular disease ‘runs in families’. Already in 
the 60’s studies showed that the risk for ischemic heart disease was seven times 
higher for relatives of CHD cases than controls (Slack and Evans 1966). In North 
Karelia, a high CVD risk area of Finland, Rissanen (1979a) estimated that the 
cumulative risk for CHD by the age of 65 was 4.5 higher for brothers and 2.6 higher 
for sisters of CHD cases when compared with control siblings. In addition, the 
clinical manifestation of the disease seemed to aggregate in families: fatal MI 
occurred more often in the family if the proband had died of the disease, and a 
similar observation was made for angina pectoris. Recently, a German study 
reported that left main coronary disease is more heritable and confers approximately 
2.5-3 times higher risk for unaffected siblings compared to other types of the disease 
(Fischer et al. 2007). The genetic contribution seems to be even stronger for 
premature or early onset CHD. In eastern Finland, the risk for having CHD by the 
age of 55 was 11.4 times higher for brothers of cases who developed the disease by 
the age of 46 compared to only 1.3 times higher for brothers whose sibling had been 
diagnosed at the age of 51 to 55 years. Aggregation of hyperlipidemia and 
hypertension in the early onset families might partially explain the higher risk in 
these families (Rissanen 1979b). A similar observation of risk factor aggregation has 
been made in the Framingham Offspring Study. In this study as well, the impact of 
sibling CVD was stronger in the younger age group ( 48 years) than in the older 
age group (odds ratio 2.22 vs. 1.33) but this difference was not significant (Murabito 
et al. 2005). Using the same study set Lloyd-Jones and colleagues (2004) reported 
that premature parental CVD was associated with 2.0 times increased risk for CVD 
for men and 1.7 times increased risk for women compared to individuals with no 
parental CVD. Nonpremature parental CVD was not as strong a predictor as 
premature CVD. Twin studies indicate that heritability of MI ranges from 0.25 to 0.6 
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and, for example, a Swedish study of 20 966 twins estimates that heritability of 
coronary death is 0.57 for men and 0.38 for women (Zdravkovic et al. 2002, Lusis 
2003). Specifically for stroke, a recent meta-analysis reported that monozygotic 
twins were more likely to be concordant for stroke than dizygotic twins and positive 
family history was a significant risk factor in case-control and cohort studies, 
although severe heterogeneity between studies was observed (Floßmann et al. 2004). 
Studies using adjustment for traditional risk factors show that also other genetic 
factors, than those affecting these traits, have a role in the risk for CVD. 
2.3.2 Important lessons from monogenic disorders 
Studies on rare Mendelian diseases that cause premature coronary artery disease 
(CAD), and abnormal lipid profiles or blood pressure have revealed a few mutations, 
which are presumed to explain a fraction of an individuals’ inherited risk for 
common, multifactorial CAD. Although there is still a large gap in our knowledge of 
the genes that are involved in susceptibility for most patients with multifactorial 
CAD, these studies have increased our understanding of the pathophysiology of the 
disease.  
Many of the rare Mendelian monogenic diseases share similar pathological 
components with the multifactorial CAD. For example, familial combined 
hyperlipidemia (FCHL) causes elevated blood cholesterol and triglyceride levels 
which make the patient susceptible for premature CAD. In the common form of 
CAD as well, altered lipid metabolism predisposes to the disease. By studying 
families with FCHL Pajukanta and colleagues (2004) were able to identify a novel 
gene, upstream transcription factor 1 (USF1), which was associated with abnormal 
lipid profiles in these families. Variation in the USF1 gene has later been associated 
with total and non-HDL-C, waist/hip ratio in both sexes and with CVD and all-cause 
mortality in females in a population sample (Komulainen et al. 2006). Similarly, 
studies on Tangier disease have identified a gene ATP-binding cassette transporter 
A1 (ABCA1), which in a truncated form causes low HDL-C levels (Bodzioch et al. 
1999). Heterozygous mutations in the ABCA1 gene are associated with HDL-C 
levels also in the general population (Frikke-Schmidt et al. 2004).  
Apart from direct population associations, studies on monogenic diseases have also 
taught us about the basic biological mechanisms related to cholesterol metabolism 
and regulation of blood pressure. Familial hypercholesterolemia, familial ligand-
defective apolipoprotein B-100, autosomal recessive hypercholesterolemia, and 
sitosterolemia are all caused by mutations in the LDL-receptor pathway. 
Understanding of the mechanisms of LDL excretion and uptake in the liver has 
facilitated development of the cholesterol lowering drugs statins. Much in the same 
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way, studies on rare Liddle’s, Gitelman’s and Bartter’s syndromes, which cause 
abnormal blood pressure, have increased our knowledge of the renal function of 
epithelial sodium channels, sodium-chloride cotransporter, and genes required for 
normal salt reabsorption in the thick ascending loop of Henle, and their role in the 
regulation of blood pressure. (Nabel 2003)  
2.3.3 Family-based findings on susceptibility loci for common CVD 
To date, (January 2008) there have been 9 published genome-wide linkage mapping 
studies on CVD. Most of them have been carried out in families with premature 
CVD. These studies have identified several candidate loci for premature MI, stroke 
or CHD (Table 5). In addition to linkage scans for CVD, several studies have 
reported results on linkage scans on CVD risk factors such as hypertension, blood 
lipid or inflammatory marker levels and type II diabetes. Regions in chromosomes 
3q13, 2q and 17p are among the few putative loci where the linkage results for CVD 
have been replicated if not at a genome-wide significance, but at a suggestive level. 
However, some of the implied loci harbour interesting candidate genes that have 
subsequently been shown to associate with the disease. For example, in chromosome 
13q12 locus, the ALOX5AP gene, which encodes 5-lipoxygenase activation protein 
(FLAP), was first identified as a candidate for premature MI and ischemic stroke in 
Icelandic families (Helgadottir et al. 2004). FLAP protein operates in a pathway 
involved in biosynthesis of leukotriene A4 (LTA4). This pathway has independently 
been implicated in the pathogenesis of atherosclerosis in humans (Spanbroek et al. 
2003) and in mouse models (Mehrabian et al. 2002). Furthermore, a variant in the 5-
lipoxygenase (ALOX5) gene has been associated with increased carotid artery intima 
media thickness (IMT) (Dwyer et al. 2004), and a haplotype in the gene encoding 
LTA4 hydrolase has been associated with modestly increased risk for MI in 
European Americans (risk ratio = 1.16) and with even greater risk in individuals 
with African origin (risk ratio = 3.57) (Helgadottir et al. 2006) lending more support 
to the role of this pathway in the aetiology of CVD. The ALOX5AP locus expresses 
some allelic heterogeneity: in Iceland and in Britain different haplotypes have been 
associated with MI while the same haplotype was associated with stroke both in 
Iceland and in Scotland and with suggestive evidence of association in Sweden 
(Helgadottir et al. 2004, Helgadottir et al. 2005, Kostulas et al. 2007). Although 
positive association dominate the reports on ALO5AP, in a German case-control 
sample haplotypes in this gene did not associate with MI (Koch et al. 2007). 
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2.3.4 Previous findings in association studies 
G e n o m e - w i d e  s t u d i e s  
Genome-wide studies augment candidate gene studies that rely on a priori 
hypothesis of biological pathways. To date, six published genome-wide association 
studies have searched for loci and variants conferring risk for coronary heart disease 
or stroke (Table 6). None of the studies found genome-wide significant association, 
but reported several interesting suggestive regions and candidate genes. An 
association in a locus in chromosome 9p21 has been found in three separate studies, 
in several independent replication study samples, implicating that this region 
harbours variants with a significant impact on risk for CAD (Helgadottir et al. 2007, 
Larson et al. 2007, McPherson et al. 2007). Of the linkage studies listed in Table 5, 
study by Wang and co-workers (2004) report a suggestive linkage to the same 
region in 9p21. Furthermore, significant association with type 2 diabetes has been 
found in the neighbouring region (Saxena et al. 2007). The most significant variants 
in the associating region do not map to any known genes and are in the same 190 kb 
LD block. There are two genes CDKN2A and CDKN2B, two exons of an mRNA 
transcript, a hypothetical methylthioadenosine phosphorylase fusion protein mRNA 
and several ESTs that are expressed in various tissues within this large block. In-
depth-sequencing of the two genes did not reveal any likely candidates for 
functional variants and further studies are needed to elucidate the role of the region 
in the development of CAD (Helgadottir et al. 2007, McPherson et al. 2007).  
In a Japanese genome-wide association study, Ozaki and colleagues (2002) 
identified lymphotoxin-α gene as a potential candidate for myocardial infarction. 
Their study design included roughly 65 700 mostly gene-based SNPs and had 
consequently less power to detect the variants identified in the more recent GWA 
studies analysing 100 000– 500 000 SNPs. Later the Japanese group reported that 
galectin-2 protein interacts with LTA. A variant (C3279T) in intron 1 of galectin-2 
encoding gene, LGALS2, is even more significantly associated with decreased risk 
of MI and this variant is associated with decreased secretion of LTA (Ozaki and 
Tanaka 2005). Replications of the associations with CHD have been more complex. 
Studies from both Asian and European populations have reported both positive and 
negative associations for LTA variants and a recent meta-analysis concluded that 
they do not have an effect on CHD risk. A drawback of the meta-analysis is that it 
did not adjust the analysis for age and sex (Clarke et al. 2006). Only one prospective 
study has studied both LTA and LGALS2 gene variants and concluded that LTA was 
not associated with CHD while LGALS2:C3279T was associated with decreased risk 
for CHD in American females (Asselbergs et al. 2007).  
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The story of LTA exemplifies how genome-wide studies can generate and augment 
hypotheses of new pathways involved in the pathophysiology of CVD, and at the 
same time, how replication in large well defined study samples in same and in 
different populations is essential for the validity of this type of study design. 
C a n d i d a t e  g e n e  s t u d i e s  
The field of cardiovascular research and complex diseases in general is famous for a 
plethora of association studies on candidate genes and lack of replication. Until 
December, 2005, nearly 5000 candidate gene studies had investigated the 
association between MI or CAD, and 329 polymorphisms in 152 genes and reported 
their findings in international journals. Of these, 102 genes and 192 polymorphisms 
show positive and reproducible results in at least two independent populations. The 
inconsistency in the results is most likely due to underpowered studies and false 
positive findings combined with ethnic variation and sex-specific differences in the 
susceptibility genes (Mayer et al. 2007). Similarly, until January 2003, 120 studies 
had investigated the association between ischemic stroke and 51 polymorphisms in 
32 genes. Only the four most studied polymorphisms (Factor V: Leiden, 
Methylenetetrahydrofolate reductase (MTHFR): C677T, Angiotensin converting 
enzyme (ACE): insertion/deletion (I/D), Prothrombin: G20210A) showed significant 
modification of risk in the meta-analysis while the others did not (Casas et al. 2004). 
Association studies have observed that the effect magnitude of the risk-associated 
allele is often quite moderate (Altshuler and Daly 2007). Consistent association 
results for genes like APOE, APOB, nitric oxide synthase 3 (NOS3), ACE, 
plasminogen activator inhibitor-1 (PAI1 or SERPINE1), MTHFR, integrin-α-2b 
(ITGA2B), paraoxonase 1 (PON1), LPL, and CETP have inspired researchers to try 
to establish the predictive value of the combined product of several polymorphisms. 
In their approach Drenos and co-workers (2007) derived unadjusted summary risk 
estimates and allele frequencies for these SNPs from published meta-analyses and 
calculated estimated numbers of individuals with different numbers of risk 
genotypes. While it was clear based on the analysis that individuals with 6 or more 
risk alleles had an increased risk for CHD compared to individuals with 3-4 risk 
alleles, it is still unclear how much these 10 SNPs add to the predictive power of 
traditional risk factors since adjusted risk estimates were not available. 
P r e v i o u s  f i n d i n g s  o n  s e r u m  l i p i d  l e v e l s  i n  
g e n o m e - w i d e  a s s o c i a t i o n  s t u d i e s  
Several large genome-wide association studies including data from thousands of 
individuals have looked for variants influencing the variability in serum lipid levels 
(Kathiresan et al. 2007, Saxena et al. 2007, Kathiresan et al. 2008, Sandhu et al. 
2008, Wallace et al. 2008). They have confirmed the association of many already 
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known susceptibility genes but interestingly have identified only very few new 
candidate loci. For LDL-C the confirmed findings included, for example, APOB, 
APOE-C1-C4-C2 -cluster and LDLR; for HDL-C: ABCA1, cholesteryl ester transfer 
protein (CETP) and LPL, and for triglycerides: apolipoprotein A5, APOB, and LPL. 
Among the most consistent new loci is a region in chromosome 1p13, which has 
been significantly associated with LDL-C levels in three of the GWA studies 
(Kathiresan et al. 2008, Sandhu et al. 2008, Wallace et al. 2008). In ~15 200 
European samples, two SNPs rs599839 and rs646776, which are located 3’ of two 
genes, cadherin EGF LAG seven-pass G-type receptor 2 and proline/serine-rich 
coiled-coil 1, explained both around 1% of the variation in the circulating levels of 
LDL-C (Sandhu et al. 2008). Each variant allele was associated with 15% standard 
deviation (SD) decrease in LDL-C assuming SD of 1 mmol/l. The small effect this 
variant has may have prevented the study by Kathiresan and co-workers (2007) from 
identifying this locus. In their study they had only 48% power to detect an effect of 
this magnitude. This locus is a very promising new candidate for a susceptibility 
locus for CHD since, in addition to associating with the levels of a strong CHD risk 
factor LDL cholesterol, the variant allele of the SNP (rs599839) has also been 
associated with decreased risk for CHD (Samani et al. 2007). 
2.3.5 Sex-specific association results  
C V D  r i s k  f a c t o r s  
Several family and twin studies have demonstrated that many of the cardiovascular 
disease risk factors have a sexually dimorphic genetic component. Differences in 
heritabilities or the genetic variance have been presented for the following traits: 
BMI (Schousboe et al. 2003), LDL-C, HDL-C, systolic blood pressure, fasting 
insulin, height and lymphocyte count (Weiss et al. 2006). Generally, traits associated 
with body fat, diabetes and anthropometric measurements have different 
heritabilities while there are conflicting results from twin versus family studies 
concerning, for example, blood pressure (Pilia et al. 2006, McCarthy 2007).  
There are a few reported sex-specific associations between CVD risk factors and 
candidate genes. However, most of them did not conduct statistical evaluation for 
the interaction. In the French-Canadian population endothelin-1 was associated with 
HDL-C in women while there was no association in men (Paré et al. 2007). Among 
the Hutterites variations in the β3 integrin (ITGB3) gene were associated with 
lipoprotein(a) levels in women and with serotonin levels in men. In the joint 
analysis, the gene associated with both traits although there was no correlation 
between the two phenotypes highlighting the importance of sex-stratified analysis 
(Weiss et al. 2005). 
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S e x - s p e c i f i c  a s s o c i a t i o n  r e s u l t s  o n  c a n d i d a t e  g e n e s  
Previous large-scale association studies on CVD have mostly ignored formal testing 
of sex-specificity of their findings or have only studied both sexes combined. A 
study of 71 candidate genes found evidence of sex-specific association in two loci 
for men (Connexin 37: C1019T and p22phox: C242T) and two for women (PAI-1: 
4G/5G and Stromelysin-1: 5A/6A), but the authors did not report a test of interaction 
(Yamada et al. 2002). For metabolic syndrome, McCarthy and colleagues (2003) 
observed a nominally significant sex-gene interaction for nine genes and number of 
metabolic trait components (LDL receptor-related protein associated protein 1 
(LRPAP1), Thrombospondin I (THBS1), Hepatic lipase (LIPC), Acetyl-Coenzyme A 
acetyltransferase 2 (ACAT2), Prolylcarboxypeptidase (PRCP), LDLR, ITGB3, 
Prothrombin (F2), P-selectin (SELP)). For CHD, Asselbergs and colleagues (2007) 
found a female-specific association for variation in the LGLAS2 gene and 
demonstrated that the sex-gene interaction was significant at an α < 0.05 level. 
2.4 Inflammatory candidate genes of cardiovascular disease 
2.4.1 Selenoprotein S 
Selenoproteins are a group of proteins that contain a selenocysteine residue in place 
of cysteine. So far, 25 selenoproteins have been identified in humans. Most of them 
are enzymes that catalyse three types of reactions: glutathione peroxidases catalyse 
the reduction of hydrogen proxide and organic hydroperoxides thus protecting the 
cells from oxidative damage; iodothyronine deiodinases are essential in activating 
and inactivating thyroid hormones; thioredoxin reductases catalyse NADPH-
dependent reduction of oxidized thioredoxin and help the cell to regulate redox 
balance. (Behne and Kyriakopoulos 2001)  
Selenoprotein S (SEPS1, also called SELS, SELENOS, VIMP, listed as SELS in human 
genome build 18) is a protein, which protects cells from oxidative stress and regulates 
inflammatory responses. It resides in the plasma membrane and in the endoplasmic 
reticulum (ER) and regulates ubiquitin dependent protein degradation by removing 
unfolded proteins from the ER. This retro-translocation event requires a close contact 
between a VCP ATPase and a Derlin-1 protein, and SEPS1 possibly facilitates this 
interaction in the ER (Kryukov et al. 2003, Ye et al. 2004). ER stress associated 
calcium depletion, glucose deprivation and cytokines TNF-α and IL-1β regulate 
SEPS1 expression (Gao et al. 2004, Gao et al. 2006). SEPS1 expression, on the other 
hand, reduces secretion of TNF-α and IL-1β from human macrophages (Curran et al. 
2005). SEPS1 has been detected in human plasma and is secreted by hepatocytes (Gao 
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et al. 2007). As part of the unfolded protein response machinery SEPS1 has an 
important role in protecting the cells and, possibly through this role, protects human 
macrophages in vitro from ER stress induced apoptosis (Kim et al. 2007). 
The SEPS1 gene is located in chromosome 15q26.3 and contains six exons. The 
protein consists of 189 amino acids and selenocysteine is the second to last one in 
the C-terminus (Kryukov et al. 2003). SEPS1 promoter has two nuclear factor 
kappa-B (NF-κB) transcription factor binding sites and an ER stress response 
element (ERSE) which overlaps with the other NF-κB site (Gao et al. 2006) (Figure 
7). NF-κB participates in hepatic synthesis of acute phase proteins, immune defence, 
and stress response by regulating transcription of several genes and has been implied 
in the development of CVD in many different pathways (Pahl 1999, Ahn et al. 
2007). Both cytokines TNF-α and IL-1β, and ER stress (inhibition of protein 
glycosylation) induce SEPS1 promoter. It is likely that cytokine induction operates 
via NF-κB and ER stress through ERSE element, but unlike some promoters with 
multiple transcription factor binding sites, these elements do not act cooperatively in 
the SEPS1 promoter (Gao et al. 2006). 
 
Figure 7. Selenoprotein S (SEPS1) gene region. A) Location of exons and a selenocysteine 
residue in the SEPS1 gene (to scale). The open boxes indicate two major alternative splice 
variants in the 3’ end according to the AceView genes (http://www.ncbi.nlm.nih.gov/ 
IEB/Research/Acembly/) B) The promoter area indicating nuclear factor kappa B (NFκB) 
binding sites and endoplasmic reticulum stress elements (ERSE). 
Exon: 1 2 3 4 6
-500 bp +3500 bp +6000 bp
NF-κB site 2
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Three SNPs (rs28665122, rs4965814, rs4965373) in the SEPS1 gene region 
associate with plasma concentrations of IL-1, TNF- and IL6. Variant rs28665122 
(G>A) is located near the ERSE element and in the middle of an ERSE-II-like 
element. During ER stress caused by inhibition of protein glycosylation, the 
presence of the A-allele reduces SEPS1 promoter activity in HepG2 hepatocytes and 
the more frequent G-allele is required for the normal ER stress response. The minor 
allele A is associated with increased cytokine concentrations (Curran et al. 2005). 
2.4.2 Interleukin 6 -related genes 
I n t e r l e u k i n  6  
Interleukin 6 is a pleiotropic cytokine that is a potent mediator of inflammatory 
processes and especially the acute-phase response (Heinrich et al. 1990). Several 
mechanisms including infection, cytokines IL1 and TNF-α, INF-γ, bacterial 
endotoxins and catecholamines induce its synthesis (van Deventer et al. 1990, Ng et 
al. 1994, Sanceau et al. 1995). Elevated levels of IL6 are associated with increased 
risk for myocardial infarction in healthy men independent of the levels of CRP 
(Ridker et al. 2000). Inflammatory markers CRP and IL6 have been associated with 
carotid atherosclerosis both prospectively and retrospectively (Elias-Smale et al. 
2007, Lee et al. 2007, Thakore et al. 2007).  
The interleukin 6 gene is located in chromosome 7p15.3 (Table 7). Variation in the 
gene has been associated with IL6 levels and haplotypes within the gene region have 
been associated with transcriptional regulation of the gene (Terry et al. 2000, 
Walston et al. 2007). Some studies have found an association between variation in 
the IL6 gene and CVD outcome (Georges et al. 2001, Humphries et al. 2001), while 
others have not (Walston et al. 2007). In particular, a SNP in the promoter region 
(-174G>C, rs1800795) has been widely studied. Recently a meta-analysis concluded 
that IL6: -174G>C SNP is not associated with CHD (Sie et al. 2006). It is possible, 
however that smoking is a significant modifier of the effects of IL6. Thakore and 
colleagues (2007) observed a significant interaction between smoking status and IL6 
levels and internal carotid artery IMT, and both Georges (2001) and Rosner and 
colleagues (2005) observed a significant interaction with the risk for MI. The meta-
analysis was not stratified according to smoking, but in the same report, the authors 
investigated this relationship in a prospective cohort of 463 incident cases and 
approximately 5 500 event-free individuals and found no association in smokers nor 
in non-smokers. 
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Table 7. Interleukin 6 -related CVD candidate genes in this study. 
Gene Symbol Location Exons Genomic 
coverage (kb)a,b
Polypeptide length 
(amino acids)b 
Angiotensin converting enzyme ACE 17q23.3 25 20.5 1306 
Antiotensin II receptor, type I AGTR1 3q24 2 45.1 359 
Interleukin 6 IL6 7p15.3 5 4.8 212 
C-reactive protein CRP 1q23.2 2 2.3 224 
Fibrinogen alpha FGA 4q32.1 6 7.6 866 
Fibrinogen beta FGB 4q32.1 8 8.1 491 
Fibrinogen gamma FGG 4q32.1 9 8.2 453 
a According to AceView (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) all genes exhibit 
  alternative transcript lengths or alternative splicing 
b From USCS Gene Sorter (http://genome.ucsc.edu) 
 
T h e  r e n i n - a n g i o t e n s i n - s y s t e m  
The Renin-angiotensin-system (RAS) is an important regulator of cardiovascular 
hemodynamics and is also involved in the development of cardiovascular disease. In 
this system, renin cleaves angiotensinogen to form angiotensin I (Ang I) and ACE 
then converts Ang I into vasoactive angiotensin II (Ang II). ACE also inactivates a 
vasodilator agent bradykinin efficiently regulating the RAS system. Angiotensin II 
receptor type I (AT1R, gene: AGTR1) is the main mediator of the physiological 
effects of Ang II (Davis and Roberts 1997) and also mediates the Ang II stimulated 
release of IL6 from human adipocytes via activation of NF-κB (Skurk et al. 2004). 
The effect of the RAS system on atherosclerosis include the stimulatory effect of 
Ang II via AT1R1 on expression of VCAM1 in endothelial cells (Pueyo et al. 2000), 
and secretion of matrix metalloproteinase by human VSMCs (Browatzki et al. 
2005). Furthermore, oxidized LDL has been shown to increase the expression of 
AGTR1 in human coronary artery endothelial cells and VSMCs suggesting a link 
between the progression of atherosclerosis and AT1R (Li et al. 2000).  
The genes encoding components of the RAS system are located in chromosomes, 
17q23.3 (ACE), 3q24 (AGTR1) (Table 7), and 1q42-q43 (angiotensinogen). Genetic 
polymorphisms in RAS system and their relation to the risk for hypertension and 
CVD have been studied extensively. In particular, ACE insertion/deletion 
polymorphism in the 16th intron of the gene and AGTR1: A1166C (rs5186) in 3’-
untranslated region (UTR) of the gene have been a focus of wide interest. The ACE: 
I/D polymorphism is associated with levels of ACE enzyme (Rigat et al. 1990). In 
meta-analysis reports these two variants were associated with increased risk for MI: 
ACE I/D homozygosity for the D-allele with pooled odds ratio (OR) of 1.21 (95% 
confidence interval (CI): 1.11-1.32) and C-allele of AGTR1: A1166C with an OR 
1.13 per allele (CI: 1.01-1.23) (Agerholm-Larsen et al. 2000, Ntzani et al. 2007). 
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Some studies have also found epistatic interactions between genes in the RAS 
system (Ye et al. 2003, Tsai et al. 2007).  
C - r e a c t i v e  p r o t e i n  a n d  f i b r i n o g e n  
Interleukin 6 is the main inducer of the hepatic production of CRP and fibrinogen 
(Heinrich et al. 1990). CRP and fibrinogen are both acute phase proteins and 
increased levels of both of them have been associated with increased risk for CVD 
and MI (Danesh et al. 2004, Mannila et al. 2004). In addition to having 
inflammatory effects, fibrinogen is an essential component of the coagulation 
cascade and may contribute to the risk for CVD via increased risk for coagulation 
(hypercoagulability hypothesis), lesion progression and enhanced endothelial 
dysfunction (Spronk et al. 2004). 
The CRP gene is located in chromosome 1q23.2 (Table 7). Several variants in the 
gene have been associated with CRP levels in plasma. Of these variants a tri-allelic 
SNP in the promoter region has been confirmed to be functional (Carlson et al. 
2005, Miller et al. 2005, Szalai et al. 2005, Kathiresan et al. 2006a). SNP and 
haplotype analysis in the CRP locus have found both supporting and opposed 
evidence for the effect of CRP gene variants and the association with CAD (Miller 
et al. 2005, Kardys et al. 2006, Lange et al. 2006). 
Fibrinogen is a dimeric protein with each unit comprising of three polypeptides Aα, 
Bβ and γ. Genes encoding the polypeptides, FGA, FGB and FGG, are located in 
chromosome 4q28 in a tight cluster (Table 7). Transcription of the genes is 
coordinated and synthesis of the β-chain is the rate-limiting step of fibrinogen 
synthesis (Roy et al. 1990). Genetic polymorphisms in the FGB gene but not FGA or 
FGG have been associated with the levels of fibrinogen (Kathiresan et al. 2006b). 
Several studies have investigated the relationship between genetic variation in the 
fibrinogen gene locus and the risk for CVD. Most studies have focused on the 
promoter region of FGB gene and to a SNP -148C>T (rs1800787). A recent meta-
analysis concluded that this variant is not associated with CHD (Smith et al. 2005). 
Studies using haplotypes across the fibrinogen gene cluster have identified a risk 
associating haplotype from FGG and FGA genes (Mannila et al. 2005) and 
contradicted the role of haplotypes in the FGG gene (Uitte de Willige et al. 2006) 
and in the whole fibrinogen gene cluster (Kathiresan et al. 2006b). 
I n t e r a c t i o n s  b e t w e e n  i n t e r l e u k i n  6  - r e l a t e d  g e n e s  
IL6 participates in many reactions relevant to atherosclerosis and risk for CVD. The 
relationship between IL6 and the renin-angiotensin system is complex and 
apparently works in two directions. The Ang II induced hypertension is partially 
controlled by IL6 (Coles et al. 2007); Ang II induces secretion of IL6, facilitated by 
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AT1R, from leukocytes ex vivo during oxidative stress (Willemsen et al. 2007) and 
from human VSMCs in vitro (Kranzhöfer et al. 1999); and, on the other hand, IL6 
induces expression of AGTR1 in rat VSMCs both in vitro and in vivo (Wassmann et 
al. 2004).  
Polymorphisms in the IL6 gene have been associated with circulating levels of CRP 
and fibrinogen (Vickers et al. 2002, Ferrari et al. 2003, Sie et al. 2006, Walston et al. 
2007, Wong et al. 2007). Furthermore, a Korean study demonstrated that variants 
IL6: 572C>G (rs1800796) and CRP: 717G>A (rs2794521), +1444C>T 
(rs1130864), and +2147A>G (rs2808631) show additive effects on serum hsCRP 
and insulin concentration, and measurement of insulin resistance (homeostasis 
model assessment, HOMA-IR) (Paik et al. 2007).  
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3 AIMS OF THE STUDY 
The aim of the present study was to investigate the inflammatory mechanism and its 
relation with cardiovascular disease in large-scale genetic studies. The following 
specific aims were addressed: 
 
1. To identify underlying causes of variation in the DNA extraction yield in 
large population surveys (I). 
2. To examine the relationship between the risk for CVD and common 
variants in the selenoprotein S gene (II), and to analyse the function of the 
downstream polymorphism (unpublished data). 
3. To study the risk for CVD and 46 different CVD candidate genes related to 
inflammation, thrombosis and lipid and energy metabolism focusing on a 
subset of these genes all related to interleukin 6 by using two prospectively 
followed Finnish case-cohort sets (III). 
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4 MATERIALS AND METHODS 
4.1 Study subjects 
4.1.1 Health 2000 survey 
The Health 2000 survey aims to assess the health and functional capacity of Finns. 
The cohort is based on a nationally representative clustered random sampling drawn 
from the Finnish population register and included 8028 individuals aged 30 years 
and above. Of these 6968 (87%) were interviewed at home and after the interview 
6770 (84%) either participated in a clinical examination or were examined at home. 
Fasting blood samples were drawn only from those participating in clinical 
examination. The study was approved by the local ethics committees, the 
participants signed an informed consent and the principles of the Helsinki 
Declaration were followed (Aromaa and Koskinen 2002). A whole blood sample for 
DNA extraction was available from 6451 (80%) individuals. 
4.1.2 FINRISK 92 and 97 surveys 
The FINRISK surveys are designed to assess the risk factors levels of chronic, 
noncommunicable diseases including cardiovascular disease in defined geographical 
areas. The studies cover south-western, southern, north-eastern (1992 & 1997) and 
northern (1997) parts of Finland. The survey samples were drawn from the National 
Population Register and the selection was stratified by age, sex and geographical 
area. Participants of these two studies were 25 to 64 years of age at the baseline 
examination (25-75 in the FINRISK 97 study) and the participation rates were 76% 
(n = 5999) and 73% (n = 8141), respectively. Both cohorts were followed up for 
fatal or non-fatal coronary event or ischemic stroke or venous thromboembolic 
events through the myocardial infarction and stroke registers (Salomaa et al. 2003, 
Sivenius et al. 2004), the National Hospital Discharge Register and the National 
Causes of Death Register. All participants gave their informed consent, both studies 
were approved by the local ethics committees, and they followed the principles of 
the Helsinki Declaration. In the FINRISK 97 cohort, a whole blood sample for DNA 
extraction was available from 7982 individuals (69% of the original selection). 
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C a s e - c o h o r t  s e l e c t i o n  
The two sample sets for studies II and III were derived from the two independent 
FINRISK cohorts recruited and sampled in 1992 and 1997 and followed until 2001 
and 2003, respectively (Vartiainen et al. 2000). From these two cohorts, two 
separate sample sets were selected for genotyping in a case-cohort design (n = 999 
and 1223, respectively). The both FINRISK cohorts participated in a multi-national 
project MORGAM examining genetic predisposition to CHD and the stroke and the 
case-cohort selection in this study was made according to principles agreed to in the 
project (Evans et al. 2005, Kulathinal et al. 2007). The selection included individuals 
with history of myocardial infarction or ischemic stroke defined as prevalent cases 
and individuals who suffered from a cardiovascular disease (myocardial infarction, 
unstable angina or ischemic stroke) event during the follow-up period defined as 
incident cases. Individuals who had suffered from a venous thromboembolic event 
or had died during the follow-up were also genotyped. A sex and geographic region 
matched random subcohort was also drawn from both of the original cohorts with 
unequal sampling probabilities so that their age distributions were similar to the 
cases. These subcohorts represented the general population of the areas included in 
the study. Figure 8 presents the design of studies II and III with number of 
individuals in each study end-point group from study III. 
4.2 Laboratory procedures and statistical analysis 
4.2.1 Methods in publications 
Table 8 lists the methods used in this study. 
4.2.2 Biochemical markers 
Serum lipid levels were measured from fresh samples using routine enzymatic 
methods (CHOD-PAP, Monotest, Boehringer, Mannheim, Germany). Inflammation 
markers hsCRP, IL6 and TNF-α were measured in the FINRISK 92 cohort with the 
solid-phase cheminoluminescent immunometric assay (Immulite®, Diagnostic 
Products Corporation, Los Angeles, USA) and hsCRP with an immunoassay 
(Sentinel Diagnostics, Milan, Italy) using the Architect c8000 instrument (Abbott 
Laboratories, Irving, USA) from the FINRISK 97 samples. CRP measurement was 
not available from 167 individuals (16.7%) in the FINRISK 92 and from 67 
individuals (5.5%) in the FINRISK 97 cohort. Careful examination of FINRISK 92 
cohort revealed no significant differences in clinical or laboratory characteristics 
between individuals with and without CRP measurement. 
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Figure 8. FINRISK study regions and number of selected subjects in study III. The 
analysis set included an age-weighted, sex-and geographic region stratified, randomly 
selected control subcohort representing the study population, fatal and non-fatal incident 
ischemic stroke and coronary heart disease cases, and individuals who died during the 
follow-up. The different end-point groups are not mutually exclusive. 
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Table 8. Methods used in the present study. 
Method Original publication 
Study samples  
Health 2000 I 
FINRISK 97 I 
FINRISK 92 & 97 Case-cohort sample set II, III 
Laboratory procedures and measurements  
DNA extraction I, II 
DNA sample quality control  
Spectrophotometry I, II, III 
PicoGreen measurement II, III 
Polymerase chain reaction (PCR) II, III 
Whole genome amplification II, III 
Agarose gel electrophoresis III 
Allele-specific primer extension -based micro array III 
Sequenom MassArray II, III 
TaqMan SNP genotyping II, III 
Biochemical measurements II, III 
Analysis programs  
SNPsnapper III 
Primer3 III 
Sequenom AssayDesigner (V3.0.1.1 beta)  II, III 
Sequenom MassaArray Typer (v. 3.4)  II, III 
ABI 7900HT SDS 2.2  II, III 
Pedcheck 1.1 II, III 
Alibaba2 II 
P-match II 
Statistical methods and programs  
t-test I 
Linear regression I, III 
Cox’s proportional hazard model, time-to-event analysis II, III 
Analysis of covariance II 
Wilcoxon–Mann–Whitney rank test II 
Phase 2.1 II, III 
haplo.glm III 
SNPSpD II 
False discovery rate III 
Haploview 3.32 II, III 
SPSS 11.0 I 
SAS 9.1 for Windows II, III 
R-statistical environment III 
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Interleukin 6 measurements were available only from 309 subcohort individuals free 
of baseline CVD from the FINRISK 92 cohort. Serum fibrinogen levels were also 
available only from a selected subset of individuals: in the FINRISK 92 cohort, from 
203 women and 377 men participating in the FINRISK 92 Hemostasis study 
(Rajecki et al. 2005), and in the FINRISK 97 cohort only from 528 men of the PAIS 
sub-sample (Jousilahti et al. 2001). Among men, the baseline characteristics of these 
groups differed significantly: FINRISK 97 participants were older (p < 0.0001), 
were more often daily smokers (p < 0.0001), had a history of diabetes (p = 0.046) 
and CVD (p < 0.0001), had hypertension (p = 0.017), lower levels of triglycerides (p 
= 0.002), HDL-C to total cholesterol ratio (p < 0.0001), and hsCRP (p = 0.0004) and 
higher levels of fibrinogen (p < 0.0001). Fibrinogen was measured from snap-frozen 
plasma with the Clauss method (Clauss 1957) in the FINRISK 97 cohort and in the 
FINRISK 92 cohort with a prothrombin time assay (IL Test PT-Fibrinogen, 
Instrumentation Laboratories, Milan, Italy) measuring the scattered light from the clot.  
4.2.3 DNA extraction and quality control 
EDTA anticoagulated whole blood samples were stored in -20ºC in both the Health 
2000 and FINRISK surveys. DNA from the FINRISK samples was extracted with a 
phenol-chloroform protocol modified from Vandenplas and colleagues (1984) and 
DNA from the Health 2000 samples with Gentra Puregene reagents (QIAGEN, 
GmbH, Hilden, Germany). We quantified the accurate concentration of DNA 
aliquots prior to normalization with the PicoGreen dsDNA Quantitation Kit 
(Invitrogen (Molecular Probes), Carlsbad, USA) and amplified samples with low 
yield of DNA with GenomePhi whole genome amplification kit (GE Healthcare 
(Amersham Biotech), Chalfont St. Giles, UK). We determined the sex from the 
DNA sample with sex chromosomal markers and excluded all samples with 
discrepant results. Furthermore, we genotyped additional autosomal microsatellite 
markers in order to identify samples contaminated with another DNA. 
4.2.4 Candidate genes and variant selection 
Study II focused on the SEPS1 gene and study III on IL6 -related genes: ACE, 
AGTR1, CRP, IL6, FGA, FGB, and FGG. All the genes investigated in study III are 
listed in Table 9. We selected common (>5%) variants for study II from dbSNP 
(www.ncbi.nlm.nih.gov/SNP/) and HapMap (The International HapMap Consortium 
2003) databases based on available valid frequency data, haplotype information 
aiming at an even distribution along the gene. In addition, variants from previous 
association reports were included. In study III we searched the SeattleSNP variation 
discovery database (SeattleSNPs) and selected all haplotype bin tagging SNPs 
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(tagSNP) with >5% minor allele frequency in the European decent sample to fully 
capture the variation in the genes. In addition, we selected all SNPs with prior 
evidence of association with CVD, metabolic syndrome or protein product levels. 
For genes, such as, AGTR1 where tagSNP data was not available in the SeattleSNP 
database, we selected the SNPs based on frequency, validation data and location 
from the dbSNP database. Once HapMap phase I data became available, we also 
used the additional information it provided. From the ACE gene we also genotyped 
the Alu insertion/deletion polymorphism in the FINRISK 92 sample. Table 10 
presents variants selected for IL6 -related genes. 
4.2.5 Variant genotyping and quality control 
This study utilized three different genotyping methods. Primarily we used the 
Sequenom MassArray system (Sequenom, San Diego, USA), either with the 
homogeneous Mass Extension (hME) reaction or the iPLEX reaction. For the hME 
genotyping we used 5-7.5 ng of genomic and 10 ng of WGA DNA. The second 
genotyping method was allele-specific primer extension on microarray (Pastinen et 
al. 2000) with 10 ng of genomic or WGA DNA. A few variants were genotyped 
using the TagMan SNP genotyping system (Applied Biosystems, Foster City, USA). 
The ACE: I/D polymorphism was genotyped using PCR amplification and 
separation on an agarose gel. The genotyping sample included 5% of blinded 
duplicates and each 96-well plate included two open duplicate samples, two CEPH 
(Centre d'Etude du Polymorphisme Humain) controls and two negative controls. In 
addition, WGA samples were genotyped in duplicate. 
4.2.6 Bioinformatic analysis of transcription factor binding 
We used two transcription factor (TF) binding site prediction programs Alibaba2 
and P-match to investigate putative TFs interacting with 36 bp surrounding sequence 
of variant rs7178239. Alibaba2.1, by Niels Grabe, utilizes the TRANSFAC 4.0 
library of known TF-binding site alignments to predict binding the TFs with the 
target sequence. (http://www.gene-regulation.com/pub/programs.html#alibaba2) We 
used three different prediction conditions: 1) loose criteria with pair-wise similarity 
score 36, matrix width 10 bp, minimum number of sites = 4, low matrix 
conservation, 1% similarity between the sequence and matrix, factor class level = 
Family; 2) medium tight criteria: pair-wise similarity score 50, matrix width 10 bp, 
minimum number of sites = 4, medium matrix conservation, 1% similarity between 
the sequence and matrix, factor class level = Subfamily; 3) tight criteria: pair-wise 
similarity score 50, matrix width 10 bp, minimum number of sites = 4, medium  
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Table 9. Selected candidate genes in study III. 
Pathway and genes Gene symbol Location 
Inflammation & thrombosis   
carboxypeptidase B2 (plasma) CPB2 13q14.12 
CD14 molecule CD14 5q31.3 
coagulation factor II (prothrombin) F2 11p11.2 
coagulation factor II (thrombin) receptor F2R 5q13.3 
coagulation factor V (proaccelerin, labile factor) F5 1q24.2 
coagulation factor VII (serum prothrombin conversion accelerator) F7 13q34 
coagulation factor X  F10 13q34 
coagulation factor XII  F12 5q35.3 
coagulation factor XIII, A1 polypeptide F13A1 6p25.1 
C-reactive protein, pentraxin-related CRP 1q23.2 
fibrinogen alpha chain FGA 4q32.1 
fibrinogen beta chain FGB 4q32.1 
fibrinogen gamma chain FGG 4q32.1 
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) ITGA2 5q11.2 
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 17q21.32 
intercellular adhesion molecule 1 (CD54), human rhinovirus receptor ICAM1 19p13.2 
interleukin 1, alpha  IL1A 2q13 
interleukin 1, beta  IL1B 2q13 
interleukin 10  IL10 1q32.1 
interleukin 6 (interferon, beta 2)  IL6 7p15.3 
lectin, mannose-binding, 1 LMAN1 18q21.32 
lymphotoxin alpha (TNF superfamily, member 1) LTA 6p21.33 
plasminogen activator, tissue PLAT 8p11.21 
protein C (inactivator of coagulation factors Va and VIIIa) PROC 2q14.3 
selectin E (endothelial adhesion molecule 1) SELE 1q24.2 
selectin L (lymphocyte adhesion molecule 1) SELL 1q24.2 
selectin P (granule membrane protein 140kDa, antigen CD62) SELP 1q24.2 
selenoprotein S  SEPS1 15q26.3 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor 
    type 1), member 1 
SERPINE1 7q22.1 
thrombomodulin  THBD 20p11.21 
tumor necrosis factor (TNF superfamily, member 2) TNF 6p21.33 
vascular cell adhesion molecule 1  VCAM1 1p21.2 
Lipids & energy    
apoliprotein A-V APOA5 11q23.3 
apoliprotein E  APOE 19q13.32 
forkhead box C2 (MFH-1, mesenchyme forkhead 1) FOXC2 16q24.1 
lactase  LCT 2q21.3 
lipin 1 LPIN1 2p25.1 
neuropeptide Y  NPY 7p15.3 
thioredoxin interacting protein TXNIP 1q21.1 
upstream transcription factor 1 USF1 1q23.3 
Others    
5,10-methylenetetrahydrofolate reductase (NADPH) MTHFR 1p36.22 
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 ACE 17q23.3 
angiotensin II receptor, type 1 AGTR1 3q24 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 APOBEC2 6p21.1 
fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood 
    group) 
FUT3 19p13.3 
klotho  KL 13q13.1 
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Table 10. Selected variants in the interleukin 6 -related genes. 
Gene Variant Alleles Alias Location Amino 
acid 
change 
Minor 
allele 
frequencya 
ACE rs4293 G>A  Intron  0.49 
 rs4298 C>T  Coding exon N/N 0.01 
 rs4320 G>A  Intron (boundary)  0.43 
 indel Del>Ins ACE I/D Intron  0.41b 
AGTR1 rs275652 T>G M-713C Promoter  0.14 
 rs1492078 C>T C-521T Promoter  0.32 
 rs2276735 G>A  Intron  -c 
 rs1492101 G>A  Intron  0.18 
 rs3772616 C>T  Intron  0.2 
 rs388915 A>G  Intron  0.21 
 rs5182 T>C M573C Coding exon L/L 0.41 
 rs5186 A>C A1166C 3’ UTR  0.18 
 rs380400 A>G  3’ UTR  -c 
CRP rs2794521 T>C -717A/G Promoter  0.2 
 rs3091244 G>A>T -286C/T/A, -390C/T/A Promoter  0.36 / 0.10 
 rs1800947 C>G +1059G/C Coding exon L/L 0.06 
 rs1130864 G>A +1444C/T 3' UTR  0.34 
 rs1205 C>T +1846G/A 3' UTR  0.38 
 rs3093075 G>T  3'   0.07 
FGA rs2070006 C>T  Promoter  0.47 
 rs2070016 T>C  Intron  0.14 
 rs2070018 A>G  Intron (boundary)  0.15 
 rs6050 T>C  Coding exon A/T 0.31 
 rs2070022 G>A  3' UTR  0.22 
FGB rs1800788 C>T  Promoter  0.25 
 rs1800787 C>T -148C/T Promoter  0.19 
 rs2227412 A>G  Intron  0.19 
 rs2227439 C>T  3'   0.15 
 rs1044291 C>T  3'   0.23 
FGG rs1800792 T>C  Promoter  0.31 
 rs2066860 C>T  Intron  0.02 
 rs2066861 C>T  Intron  0.3 
 rs1049636 A>G  Intron (boundary)  0.39 
IL6 rs2069825 +CT>-CT  Promoter  0.49 
 rs2069827 G>T  Promoter  0.26 
 rs1800796 G>C -572G/C Promoter  0.03 
 rs1800795 C>G -174G/C Promoter  0.46 
 rs2069840 C>G  Intron  0.23 
 rs1554606 T>G  Intron  0.43 
a Estimated in the combined subcohort of both sample sets. 
b Estimated only in the FINRISK 92 subcohort.  
c Success rate < 95%. 
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matrix conservation, 100% similarity between the sequence and matrix, factor class 
level = Subfamily. 
P-match, by Dmitry Chekmenev, Carla Haid and Alexander Kel, predicts TF 
binding using TRANSFAC 6.0 library and combines both pattern matching and 
nucleotide weight matrix approaches. (http://www.gene-regulation.com/pub/ 
programs.html#pmatch) We used TF-binding prediction with two levels of 
stringency: cut-off to minimize false positive matches and a less stringent criterion 
with a cut-off to minimize false positive matches.  
4.2.7 Electrophoretic mobility shift assay 
Twenty micrograms of single stranded allele specific sense and antisense 
oligonucleotides for the rs7178239 (5'-GCTACTTCAAAGAGAAG[C/G]GGGCTT 
AACCTGTATCAA-3'), non-specific competitor oligo containing a NF-κB binding 
site (5'-CCCACGTGTGATGGAAAGTCCAAAATTCTACAGGAGTCT-3') and an 
oligo where the NF-κB binding site was mutated (3'- CCCACGTGTGATTTAAAG 
TCCAAAATTCTACAGGAGTCT-5'), were annealed in buffer containing 10 mM 
Tris-HCl, pH 8.0 and 200 mM NaCl. The double stranded oligos were first 
precipitated using 3M sodium acetate (pH 5.2) and absolute ethanol, diluted in 
1xTris-EDTA (TE) buffer (pH 8.0), and then purified by electrophoresis through a 
15% polyacrylamide gel, eluted from the gel, filtered with Costar Spin-X columns 
(Corning, Massachusetts, USA), and precipitated as previously. A total of 100 ng of 
the oligos were labelled with 48μCi of [γ-32P]ATP (Perkin Elmer, Massachusetts, 
USA) using 8U of T4 polynucleotide kinase (New England Biolabs, Massachusetts, 
USA). End-labelled double-stranded oligos were purified from free ATP with 
QIAquick Spin columns (QIAGEN GmbH, Hilden, Germany) according to the 
manufacturer's instructions and eluted in 1xTE buffer. 
Electrophoretic mobility shift assay (EMSA) reactions were set up in Gel Shift 
Binding Buffer (Promega, Wisconsin, USA) with 3 μg of HeLaScribe Nuclear 
Extract (Promega). For competition assays 0.5-, to 10-fold molar excess of cold 
competitor oligo, or non-specific oligo containing a NF-κB binding site, was added. 
The mix was incubated on ice for 10 minutes after which radioactively labelled 
oligos were added, incubated at room temperature for 1h and separated on 4% 
PAGE in 0.25x Tris-Borate-EDTA buffer at 200V for 1.5 h. The dried gel was 
exposed to X-ray film at -70°C overnight.  
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4.2.8 Statistical analysis 
In studies II and III we assessed deviations from the Hardy-Weinberg equilibrium in 
the subcohort by using χ2-statistic with 1 degree of freedom for bi-allelic SNPs and 
with 3 degrees of freedom for the tri-allelic SNP (p < 0.05 (II), p < 0.01 (III)). All 
variants except SEPS1: rs4965814 (in II) followed the equilibrium. The extent of 
linkage disequilibrium at each locus was estimated with r2 and D’ statistics using 
program Haploview (v3.2). (Barrett et al. 2005) 
We studied the relationship of the variant allele of each SNP and CHD, CVD (CHD 
and ischemic stroke combined) and all-cause mortality (II only) with time-to-event 
analysis using the weighted Cox’s proportional hazard model. The model included 
subcohort sampling probabilities as weights (Kim and De Gruttola 1999) and 
variance correction based on the Barlow method (Barlow 1994) (in study II). We 
adjusted the analysis with sex and cohort when applicable, together with traditional 
CVD risk factors: history of diabetes, presence of absence of high blood pressure 
(individuals with medication for high blood pressure or systolic blood pressure > 
140 mmHg or diastolic blood pressure > 90 mmHg), HDL-C to total cholesterol 
ratio (in II), HDL-C (in III), non-HDL-C (in III), daily smoking and body-mass 
index. In study II, the analyses were stratified according to known east-west 
difference in the incidence of CVD and distribution of the CVD risk factors 
(Salomaa et al. 1996) while in study III the western, eastern and northern regions of 
Finland were included as covariates. Prevalent CVD cases were excluded from time-
to-event analyses. Study II used a dominant model of variant allele effect in all its 
genetic analyses and study III explored the genetic effect with recessive, dominant 
and multiplicative models. The analysis strategies in studies II and III were 
different: in study II we examined Cox’s models first in the FINRISK 92 cohort 
separately in men and women and then replicated the findings in the FINRISK 97 
cohort and estimated the hazard ratio in a joint analysis of both cohorts. In study III 
both men and women were first analysed together and in the second phase, a formal 
test of genotype-sex interaction was carried out. We defined interaction as 
significant (p  0.01) departure from the recessive, dominant and multiplicative 
models. Furthermore, we tested cohort-genotype interaction with a similar method. 
The SAS statistical software (version 9.1. for Windows) (SAS Institute Inc., Cary, 
USA) procedure PHREG was used in the time-to-event analysis of study II, whereas 
the R statistical environment and the coxph function of the package survival and its 
robust variance estimator was used in study III (R Development Core Team 2006).  
Study II analysed the relationship between three inflammatory markers hsCRP, IL6, 
TNF-α and obesity related measures BMI and WHR, and genetic variation in the 
SEPS1 locus by using analysis of covariance. The analysis was adjusted for age and 
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geographic region, and when applicable, for sex and cohort. It was carried out 
separately in incident CVD cases and subcohort members free of disease. In study 
III we applied linear regression models adjusted for cohort, age, geographic region, 
and sex in subcohort members free of baseline CVD. The quantitative CVD risk 
factors analysed were serum total cholesterol, HDL-C, triglycerides, LDL-C, mean 
blood pressure (average of systolic and diastolic blood pressure, each value based on 
two subsequent measurements), hsCRP, BMI, and WHR for all genes in study III. 
Individuals with lipid lowering medication at the baseline were excluded from lipid 
analyses and individuals with medication for hypertension from the analysis of 
blood pressure. The genetic models studied were recessive, dominant and additive 
and departure from the models was considered as an indication of genotype-sex 
interaction. In addition, we analysed in subcohort individuals whether variants in the 
fibrinogen genes associated with fibrinogen levels and whether IL6 gene variants 
associated with fibrinogen levels or IL6 levels in the FINRISK 92 cohort. SAS 
statistical software was used for the analysis of fibrinogen and IL6 levels and R 
statistical environment for the rest. All analyses on quantitative variables used 
logarithmic transformation where applicable. 
Both studies used Phase 2.1.1 (Stephens et al. 2001) to estimate best-guess 
haplotypes for all individuals. The estimation was carried out separately in cases and 
subcohort individuals and only consistent results from 40 independent iterations 
were accepted. In addition, study III utilized haplo.glm function in the haplo.stats 
package of the R environment when analyzing the association between haplotypes 
and quantitative variables. 
M u l t i p l e  t e s t i n g  c o r r e c t i o n  
This study utilized two different methods for multiple testing correction. In study II, 
we estimated the effective number of variants using the SNPSpD method (Nyholt 
2004) in the combined subcohort of both FINRISK cohorts, and adjusted the 
significance threshold according to estimated number of independent SNPs. We 
applied the threshold p < 0.0125 within sex and end-point specific groups. 
Furthermore, study II used two independent cohorts for replicating the results.  
Study III applied the false discovery rate method implemented in the R package 
“fdrtool” (Strimmer 2007) by interpreting the tail area of the FDR as the expected 
proportion of null results in a given group of tests. The presented time-to-event and 
quantitative risk factor association results (apart from fibrinogen and IL6 levels) for 
joint analysis of men and women are expected to have 47% true positive findings 
(corresponding to FDR value 53%). The FDR estimation included results from all 
172 SNPs in the study III with p-value  0.01 in time-to-event analyses or with 
p < 0.01 in quantitative analysis. Study III also investigated Q-Q plots for individual 
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test statistics. Sex-genotype interaction analysis also included 172 variants and the 
reported findings with p  0.01 are expected to include 30% of true positive 
findings. However, we applied an additional criterion of nominal association at the 
p  0.01 level in time-to-event analyses or at the p < 0.01 level in quantitative 
analysis in either sex in joint analysis of both cohorts. This is likely to increase the 
proportion of true positive findings.  
4.2.9 Analytical approach for joint analysis of genetic risk factors 
Increasingly more candidate gene and GWA studies will be analysing the joint 
effects of genetic variants in the future (Daly and Altshuler 2005). Several analytical 
approaches are available for case-control studies but few can be implemented in 
case-cohort design. We wanted to investigate the joint effects of all SNPs in the IL6 
-related pathway and did this by using Cox’s proportional hazard model with 
dummy variable coding. The model asked whether the difference between having a 
variant allele from both SNPs and having the variant allele only from either of the 
SNPs was statistically significant while accounting for the more traditional risk 
factors.  
To avoid analyzing redundant data we selected only one variant from the pair of 
variants with > 80% (r2) correlation within gene or across fibrinogen gene cluster 
(excluded variants: ACE: I/D, FGA: rs2070022, FGG: rs2066861, IL6: rs1554606). 
In addition, we excluded two rare SNPs (<5% minor allele frequency) (FGG: 
rs2066860 and IL6: rs1800796) and two SNPs (AGTR1: rs2276735 and rs380400) 
due to low genotyping success rate (<95%). In the joint effect analyses variants 
rs1130864 and rs3093075 were used as proxies for the alleles A and T, (r2 = 0.997 
and 0.984), respectively, of three allelic SNP rs3091244 in the CRP gene. After 
these quality control procedures, 30 SNPs entered final analyses. We constructed 
models for all SNP by SNP combinations (30 variants, 435 tests) in a) joint analysis 
of both sexes from one cohort, b) joint analysis of both cohorts of one sex, and c) 
joint analysis of both sexes and both cohorts and excluded cohort and sex-specific 
analyses because we expected that some SNP pairs would have a very small number 
of individuals carrying variant alleles from both SNPs.  
In the joint analysis of IL6 -related genes, we controlled for the multiple testing 
using FDR implemented in the SAS procedure Multtest and with replication in two 
separate cohorts. An FDR limit <10% was applied in end-point, cohort and sex-
specific groups of time-to-event analysis including results from individual SNPs in 
the interleukin 6 -related genes and joint effects analyses. The validity of the joint 
effect findings was also evaluated by inspecting the consistency between the two 
cohorts and the two end-points. 
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5 RESULTS AND DISCUSSION 
5.1 Cardiovascular risk factors and association with the 
variation in DNA yield from whole blood samples (I) 
In the first part of this study, we observed that the distribution of DNA yield from 10 
ml whole blood sample approximates normal distribution (Figure 9) and wanted to 
investigate which factors contribute in this variation. We utilized two independent 
population-based surveys, Health 2000 (n = 6451) and a sub-sample from the 
FINRISK 97 survey (n = 1175), in which we knew that homogenous DNA 
extraction method had been used throughout the sample set. Table 11 describes the 
characteristics of the study participants.  
 
Figure 9. Distribution of DNA yields in the Health 2000 survey, (n = 6451).
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In the joint analysis of both sexes in the Health 2000 survey, the mean DNA yield 
was greater in individuals who had diabetes, hypertension, or were daily smokers or 
obese. When the analysis was stratified by sex, the result was not significant for 
obesity in females. In the FINRISK 97 survey, the only significant association 
observed was for smoking. In addition, we found a trend for increased DNA yield in 
myocardial infarction cases in men of both surveys (Table 12). 
 
Table 12. The mean yield of DNA (μg/ml of blood) by presence or absence of a disease or 
a risk factor. 
 Health 2000 FINRISK 97 
Disease or risk factor Both sexes Females Males  Males 
Diabetes N (No/Yes) 6035/374 3314/211 2721/163  1087/89 
 No, mean (SD) 41.1 (18.1) 41.0 (18.0) 41.2 (18.1)  21.4 (13.1) 
 Yes, mean (SD) 45.1 (18.8) 44.4 (20.0) 46.1 (17.1)  20.8 (12.4) 
 P-valuea <0.0001 0.014 0.001  0.69 
N (No/Yes) 6145/274 3429/103 2716/171  979/122 History of 
myocardial infarction No, mean (SD) 41.2 (18.2) 41.1 (18.2) 41.4 (18.2)  21.4 (13.0) 
 Yes, mean (SD) 42.5 (16.8) 41.5 (16.1) 43.1 (17.2)  23.7 (14.1) 
 P-valuea 0.256 0.833 0.222  0.074 
Daily smoking N (No/Yes) 5007/1444 2924/624 2083/820  898/276 
 No, mean (SD) 40.0 (17.8) 40.3 (18.0) 39.7 (17.6)  20.8 (13.0) 
 Yes, mean (SD) 45.6 (18.6) 45.2 (18.8) 45.8 (18.5)  22.9 (13.2) 
 P-valuea <0.0001 <0.0001 <0.0001  0.02 
Obesityb N (No/Yes) 4259/1339 1967/569 2292/770  750/258 
 No, mean (SD) 40.9 (17.8) 41.1 (17.7) 40.6 (18.0)  21.7 (13.1) 
 Yes, mean (SD) 42.9 (19.0) 42.4 (18.9) 43.2 (19.2)  21.8 (12.6) 
 P-valuea 0.001 0.142 0.001  0.916 
Hypertensionc N (No/Yes) 3288/2850 1379/1409 1909/1441  389/784 
 No, mean (SD) 41.0 (18.1) 41.0 (18.0) 41.0 (18.1)  21.0 (12.5) 
 Yes, mean (SD) 42.5 (17.9) 42.4 (18.1) 42.6 (17.7)  21.5 (13.3) 
 P-valuea 0.001 0.013 0.034  0.554 
a t-test 
b BMI 30 vs. <30 kg/m2 
c Systolic blood pressure  140 mmHg or diastolic blood pressure  90 mmHg 
 
In the Health 2000 survey, multivariate linear regression modelling adjusted for age, 
sex, technician and time of storage, examining each risk factor at the time, revealed 
significant association between DNA yield and BMI, daily smoking, history of 
diabetes, systolic blood pressure, triglycerides, HDL-C and history of myocardial 
infarction (data not shown). Of these, only smoking was significantly associated 
with DNA yield in the FINRISK 97 survey and the association with MI showed an 
insignificant trend (p = 0.082). Since many of the risk factors are correlated, we 
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wanted to evaluate their contribution to the DNA yield by a multivariable regression 
with a step-wise approach in the Health 2000 survey. This analysis including both 
sexes, indicated that daily smoking was associated with ~50μg increase (p < 0.0001) 
in DNA yield compared to non-smokers, history of diabetes with 33.1 μg increase 
(p < 0.001) compared to unaffected individuals, one SD increase in systolic blood 
pressure with 10.7 μg increase (p < 0.0001), one SD increase in triglycerides with 
10.2 μg increase (p < 0.0001), and one SD increase in HDL-C with 10.8 μg decrease 
(p < 0.0001) in the DNA yield. The results were similar for men and women. When 
we tested the same model in the FINRISK 97 data, we observed that smoking, HDL-
C, and triglycerides were significantly associated with the DNA yield and the trend 
was similar for systolic blood pressure. However, contrary to the results from the 
Health 2000 survey, the effect of one SD increase in triglyceride levels was 
associated with 9.9 μg decrease in the DNA yield (p = 0.012). 
In the FINRISK 97 sample, we were able to analyse the association between DNA 
yield and inflammatory markers WBC, hsCRP, SAA and fibrinogen. In a 
multivariate model adjusted for age, sex, laboratory technician responsible for the 
extraction and time of storage, WBC was significantly and positively associated 
with the DNA yield and explained 15.2% of the variation (p < 0.0001, n = 352). The 
other inflammatory markers were also associated with the DNA yield when analysed 
separately. However, when WBC was included in the multivariate model, none of 
the other markers or trait phenotypes remained significant. 
In conclusion, CVD trait phenotypes and inflammatory markers, especially WBC, 
were significantly associated with DNA yield from whole blood samples. We did 
not observe any significant factors associating with very low DNA yield. Most of 
the findings of this study are consistent in both cohorts. There are, however, a few 
discrepant results: the association of prevalent diabetes was not significant in the 
FINRISK 97 sub-sample, while it was a clearly associated in the Health 2000 
survey, and the serum triglyceride concentration was significantly associated with 
higher DNA yield in the Health 2000 survey and lower DNA yield in the FINRISK 
97 sub-sample. The most likely explanation for the first observation is the much 
smaller number of individuals with diabetes (374 vs. 89) in the FINRISK 97 sub-
sample. In addition, there was a marked difference in the mean DNA yield between 
the two cohorts. Factors, such as different extraction method and longer storage time 
before extraction, resulting in much lower DNA yield in the FINRISK 97 sub-
sample could potentially mask any borderline findings. The discrepant finding in 
triglyceride concentration could be due to differences in the length of fasting that 
were not accounted for in the analyses. It should be also noted that the FINRISK 97 
sub-sample participants are all men and the upper age limit is higher at 74 years. It is 
possible that these elderly men have additional inflammatory conditions, such as 
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dental problems or chronic bronchitis, potentially confounding the present analyses. 
Finally, we cannot exclude pure chance and multiple testing as possible explanations 
for these discrepant findings.  
Variation in the DNA yield can result in quite large unexpected differences between 
a group selected based on DNA availability and a group without selection bias. For 
example, if a study searching for genes associating with MI decides to select their 
control samples from the Health 2000 survey using only individuals without MI in 
the top quartile of  the DNA yield (n = 1536), their control sample becomes enriched 
for smokers. The frequency of current smokers is 8% higher (30.5%) in this group 
than in the whole cohort (22.5%) (p < 0.001). Similarly, these results suggest that 
other CVD risk factors would be more common in this group and most likely the 
individuals would have higher level of systemic inflammation. Adjusting for the 
known risk factors associating with variation in DNA yield will aid in balancing the 
selection bias, but unidentified confounding factors will remain a source for 
potential bias.  
Although we did not identify any factors associating with very low DNA yield, it is 
likely that they exist but are masked by relatively strong reducing effect of time of 
storage. To overcome the need to select the samples based on the amount of DNA 
(usually to avoid using samples with low DNA yield), the study should apply whole 
genome amplification to the low DNA yield samples so that they can be included in 
the analyses. 
To our knowledge, this study is first to analyse which factors, apart from storage 
time and the age of the blood sample donor, affect the DNA yield from whole blood 
samples. Unfortunately, we were able to study only men in the FINRISK 97 sub-
sample and data on inflammatory markers was only available in this subset of 
individuals. Apart from these drawbacks, our study, which analysed DNA samples 
extracted in a highly experienced central laboratory, utilized two independent 
cohorts and was able to demonstrate the same trend for the results in both cohorts, 
although two different extraction methods were used.  
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5.2 Inflammatory candidate gene selenoprotein S and the risk 
for cardiovascular disease (II) 
5.2.1 Variation in the SEPS1 gene and the risk for coronary heart 
disease and ischemic stroke 
Selenoprotein S is a membrane protein, which protects cells from oxidative stress 
and apoptosis and participates in the regulation of inflammation. SNP variants 
rs28665122, rs4965814, and rs4965373 have been shown to associate with 
circulating levels of IL-1, TNF- and IL6 and variant allele of rs28665122 reduces 
SEPS1 promoter activity (Ye et al. 2004, Curran et al. 2005, Kim et al. 2007).  
In the second part of this study, we aimed to investigate whether the common 
variation in this new interesting inflammatory candidate gene associated with the 
risk for CHD, ischemic stroke, a composite end-point CVD and total mortality in 
two independent case-cohort sample sets. The extent of LD in the gene region is low 
and of the selected six variants, four tagged three haplotype bins excluding only one 
bin with a single SNP in a repeat region based on the publicly available HapMap 
and Perlegen genotypes. The other two variants have not been genotyped in either 
project (http://gvs.gs.washington.edu/GVS/index.jsp). Figure 10 presents the 
selected variants and the haplotype structure within the SEPS1 locus. 
We found two significant associations in the time-to-event analysis. After 
controlling for the traditional risk factors, a promoter variant rs8025174 (haplotype 
H2) was associated with increased risk for CHD in women of the FINRISK 92 
cohort (hazard ratio (HR) 6.27 (95% confidence interval: 1.36–28.85, dominant 
model)), FINRISK 97 cohort (HR: 3.56 (1.06–11.99)), and in combined analysis of 
both cohorts (HR: 2.95 (1.37–6.39)). SNPSpD estimated four independent loci 
among the genotyped variants which corresponds to a significance threshold of 
p = 0.0125. The result from the combined analysis (p = 0.006) reached this level of 
significance. There was no association among men or for any other end-point in 
either sex for this variant. 
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Variant rs7178239 (in haplotype H4) was associated with increased risk for 
ischemic stroke in women. Since the number of incident stroke cases in each cohort 
was low (FINRISK 92: 33, FINRISK 97: 21), we only considered the analysis in the 
combined female sample to be meaningful. In this group, the variant allele of SNP 
rs7178239 was significantly associated with 3.35 times higher risk for ischemic 
stroke (CI: 1.66–6.76, dominant model) when adjusting for traditional risk factors 
and applying multiple testing significance threshold. A similar and significant result 
was observed also for the unadjusted model and for joint analysis of both sexes. The 
variant was not associated with ischemic stroke in men or with CHD, CVD or total 
mortality in either sex. Haplotype analysis supported findings from the individual 
SNP analyses for both variants.  
Figure 10. Genotyped variants in the SEPS1 gene. a) Haplotype and minor allele 
frequencies are estimated in the combined subcohort of both cohorts, b) The variant allele is 
encircled, c) Haplotypes with frequency <5%. Modified from Alanne M. et al. “Variation in the 
selenoprotein S gene locus is associated with coronary heart disease and ischemic stroke in two independent 
Finnish cohorts” Human Genetics 2007:122;355-65 © Springer-Verlag 2007. Printed with kind permission of 
Springer Science and Business Media. 
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5.2.2 Variation in the SEPS1 gene and quantitative phenotypes 
Variation in the SEPS1 gene region has previously been associated with inflammatory 
cytokines. (Curran et al. 2005) In our study, we investigated the association between 
the selected gene variants and inflammatory markers IL6 and TNF-α together with 
CVD trait phenotypes BMI and WHR. Adipose tissue is one of the tissues which 
secrete inflammatory cytokines and obesity can be considered to be a low-grade 
inflammatory condition. (Ferrante 2007) The only association we observed for the 
inflammatory markers was for variant rs7178239 (H4) and levels of IL6. Subcohort 
women free of disease, who carried the variant allele, had higher levels of IL6 than 
non-carriers (1.65 vs. 1.24 ng/l, p = 0.008). The result was not significant in men and 
among CVD cases and we could not observe any consistent trend. 
Several of the variants associated with BMI and WHR in the FINRISK 92 cohort but 
not in the FINRISK 97 cohort. The association with increased BMI was mostly 
evident among incident CVD cases for the variant allele of rs8025174 (Figure 11). 
We observed the same effect of the variant allele for WHR. Furthermore, variants in 
haplotype H4, including rs7178239, associated with increased WHR among women 
in the subcohort (Figure 12). Time-to-event analysis including BMI or WHR 
resulted in only a small attenuation in the hazard ratio estimates.  
5.2.3 Allele specific binding of nuclear extract according to SEPS1 
variant rs7178239 
B i o i n f o r m a t i c  a n a l y s i s  o f  t h e  r s 7 1 7 8 2 3 9  l o c u s  
The allele-specific binding of transcription factors was investigated using two TF-
binding site prediction programs, Alibaba2 and P-match. Variant rs8025174 resides 
next to a repeat region and we focused on variant rs7178239C>G. Since Curran and 
co-workers (2005) had in their study, which included re-sequencing of the gene, 
concluded that the association signal was mostly due to the effect of rs28665122, 
other variants than rs7178239 in the H4 haplotype were not included in the analysis. 
Variant rs7178239 is located outside the sequencing region. The results from both 
programs differed markedly, and did not predict the same TF-binding sites. At the 
lowest level of stringency, Alibaba2.1 predicted binding of TF Sp-1 (simian-virus-
40-protein-1) when either of the SNP alleles was present. However, with increasing 
stringency, only interaction with the G-allele remained. P-match predicted binding 
of TF C-rel with both alleles when using a cut-off to minimize false negative 
findings, but the core matrix similarity was greater with the G-allele (0.85 vs. 0.95). 
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Figure 11. Association of allelic variants in SEPS1 gene and body-mass index 
separately in both sexes and in cardiovascular cases and subcohort members free of 
disease. Analysis was adjusted for age, sex and cohort when relevant. 92, 97 and 
92&97 indicate each FINRISK cohort and their combination. Significance level: 
P<0.05*, P<0.01**, P<0.001***. Results significant at the 5% level after SNPSpD 
correction are underlined. 
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Figure 12. Association of allelic variants in SEPS1 gene and waist/hip ratio 
separately in both sexes and in cardiovascular cases and subcohort members free of 
disease. Analysis was adjusted for age, sex and cohort when relevant. 92, 97 and 
92&97 indicate each FINRISK cohort and their combination. Significance level: 
P<0.05*, P<0.01**, P<0.001***. Results significant at the 5% level after SNPSpD 
correction are underlined. 
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E l e c t r o p h o r e t i c  m o b i l i t y  s h i f t  a s s a y  
To further elucidate the function of the associated variant, we investigated whether 
the sequences exhibit allele-specific DNA-nuclear protein interactions from 
hepatocyte nuclear extract using EMSA. The results indicated specific and non-
specific interactions between the nuclear extract and the 36mer oligo. With the C-
allele we observed a DNA-protein band that was absent with the G-allele probe. 
(Figure 13, panel 1, band B) Furthermore, the binding of shared bands A, C and D 
appeared to be stronger with the G-allele. Unlabelled competitor analysis with the 
respective allele indicated that band B results from a specific DNA-protein 
interaction since the C-probe competed band B already in a small molar excess. 
Competition of band A was weaker than in bands C and D in 0.5 – 5-fold molar 
excess of the G-probe. (Figure 13, panel 2) Surprisingly, although the G-allele did 
not produce band B, competition of the C-probe with the G-allele removed the band. 
(Figure 13, panel 3) Competition experiment made vice versa did not affect binding 
of band A, but reduced the binding of bands C and D. Non-specific competition with 
the probe containing a NF-κB binding site and the probe mutated for this binding, 
indicated that the C-allele band B was specific to the sequence and did not result 
from binding of NF-κB, a common transcription factor, which has been shown to 
bind to the SEPS1 promoter (Gao et al. 2006) (Figure 13, panel 4). 
5.2.4 Conclusions and discussion of Study II  
Taken together, the results from the case-cohort analysis indicate that two genetic 
variants in the SEPS1 gene locus confer risk for CHD (rs8025174) and ischemic 
stroke (rs7178239) in women. In men, there was no indication of association for 
either of the variants suggesting female-specific genetic risk. To our knowledge, 
neither of these variants have previously been included in association studies for 
CVD. Interestingly, SEPS1: rs7178239 is located in the Finnish population in the 
same haplotype (H4) as the variant rs28665122, which has previously been 
associated with increased levels of inflammatory cytokines and transcriptional 
regulation of the gene. In this study, the variant had a borderline association with 
ischemic stroke (HR: 2.21 (1.04-4.72)). This promoter variant was not associated 
with ischemic stroke in a case-control study conducted in Germany and Italy 
(Hyrenbach et al. 2007). In the German sample, the variant allele was a little more 
common among cases (p = 0.17) whereas in Italy there was no difference. In 
addition to population and case ascertainment differences in our, German and Italian 
samples, the Italian controls were selected from the staff of the neurological hospital 
which may have caused some unobserved bias. 
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Figure 13. EMSA analysis of SEPS1: rs7178239 C>G. Arrows A, B, C and D indicate 
different sized nuclear protein-probe complexes from hepatocyte nuclear extract. 1) Allele 
C and G -specific binding patterns, 2) Competitor experiment with unlabelled respective 
probe of indicated molar excess, 3) Cross competitor analysis with allele-specific probes, 
4) Competitor analysis for allele C with unspecific competitor NFκB and mutated NFκB 
(NFκB mut). 
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The female-specificity of our results may, in part, be linked with selenium 
metabolism. Recent studies have demonstrated that in mice, expression and activity 
of other selenoproteins is affected by selenium concentration and tissue-dependent 
post-transcriptional modification and that both of these mechanisms are sexually 
dimorphic (Riese et al. 2006), and that the uptake and utilization of selenium may be 
sexually dimorphic also in humans (Méplan et al. 2007).  
Genetic variation in the SEPS1 gene locus, rs28665122 in particular, has previously 
been associated with circulating levels of cytokines in humans. In our study, 
rs28665122 and other variants in the gene did not associate with circulating levels of 
inflammatory markers IL6 and TNF-α. A major difference between this study and 
the previous study reporting the association, is that the study by Curran and 
colleagues (2005) was ascertained through an obese proband. Although the 
association was independent of BMI, this difference may have caused dissimilarity 
in the results. Furthermore, in our study, variation in the SEPS1 gene locus was 
associated with BMI and WHR in the FINRISK 92 cohort, but the association with 
the risk for CHD or stroke was not mediated through them. 
The EMSA analysis of variant rs7178239 supported the hypothesis that this gene 
region binds regulatory proteins from nuclear extract and that the binding is allele-
specific. The results suggests that the major allele C of rs7178239 binds a different 
protein from the nuclear extract than the minor allele G, but the interaction may 
involve the same protein complex, since G-allele could remove this interaction. In 
addition, band A may result from stronger sequence specific binding of the G-allele 
than C-allele, but this result needs further clarification. Bioinformatic analysis did 
not reveal any clear candidates as transcription factors with allele-specific binding.  
The CVD associated variants in this study are not located in the coding region or the 
UTR regions of the gene. It is thus likely that the mechanism by which they confer 
higher risk for CVD is related to the transcriptional regulation of the SEPS1 gene or 
that they are in high LD with such variants. Particularly, the variant rs7178239 is 
intriguing. It shows evidence of allele-specific binding of transcription factors or 
other interacting proteins and it may be located in an enhancer element. On the other 
hand, it resides in same haplotype as a promoter variant rs2866512 and the 
association result may represent the effect of the promoter variant which has 
previous functional evidence (Curran et al. 2005). The EMSA analysis is susceptible 
to false positive findings, especially when there is no prior knowledge of the 
interacting transcription factor and supershift assays are not be performed. These 
results from the variant rs7178239 thus need to be interpreted with caution. 
Functional studies on the selenoprotein S suggest that it may protect cells from 
apoptosis. (Kim et al. 2007) Macrophage, smooth muscle cell and endothelial cell 
apoptosis are important contributors to atherosclerosis development and 
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understanding of regulation of apoptotic process may lead to greater understanding 
of the pathogenesis of atherosclerosis (Choy et al. 2001, Akishima et al. 2004). 
Another way in which SEPS1 could contribute to the development of CVD is 
regulation of inflammatory processes in endothelial cells as part of the unfolded 
protein response (UPR). A recent study has demonstrated that ER stress induced 
UPR is involved in regulation of the inflammatory response in endothelial cells 
suggesting a key role in regulation of vascular inflammation and endothelial 
dysfunction (Gargalovic et al. 2006).  
In conclusion, SEPS1 is an interesting new candidate for CVD susceptibility. The 
role of genetic variation in the SEPS1 gene locus requires further experimental 
validation and replication in other population-based cohorts.
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5.3 Interleukin 6 -related candidate genes and sex-specific 
differences in the risk for cardiovascular disease (III) 
5.3.1 Association of gene variants in the interleukin 6 -related 
pathway with cardiovascular disease and -risk factors 
In study III, we investigated the association between 239 variants in 46 candidate 
genes and the risk for CHD, ischemic stroke and a composite end-point 
cardiovascular disease. This thesis focuses on the results from the interleukin 6 -
related genes ACE, AGTR1, IL6, CRP, FGA, FGB and FGG.  
Interleukin 6 is a pleiotropic cytokine that regulates inflammatory reactions. It 
induces synthesis of CRP, fibrinogens and AGTR1, and is involved in a complex 
regulatory relationship with Ang II. (Heinrich et al. 1990, Wassmann et al. 2004, 
Coles et al. 2007) Previous genetic association studies have focused mainly only on 
a few polymorphisms in each gene and we wanted to investigate what is the role of 
this pathway in the risk for CVD in a population based sample by comprehensively 
studying the common variation in these genes and their joint effects. 
In single SNP time-to-event analysis, we observed several nominally significant 
associations at the p < 0.05 level (uncorrected) and two variants in AGTR1 and FGA 
genes with p-value < 0.01 (Table 13). In addition, the results indicated that the 
variant allele carriers of SNP IL6: rs2069840 had an increased risk for CVD. The 
association was only evident in males (HR: 1.54 (1.12-2.13), p = 0.006 for combined 
analysis of both cohorts) and we identified a significant genotype sex interaction for 
CVD (p = 0.004, uncorrected). None of the other variants in IL6 -related genes 
associated consistently at the p < 0.05 level with the CVD risk in both sexes or 
showed evidence of genotype-sex interaction.  
Based on the FDR analysis, we expect 47% of the results with uncorrected p  0.01 
in the combined analysis of both cohorts and both sexes including single SNP time-
to-event and quantitative trait analysis of all SNPs included in study III (n=172) 
except fibrinogen and IL6 levels, to present true positive findings.  
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Table 13. Association of variants in the interleukin 6 -related genes (p < 0.05, 
uncorrected) with coronary heart disease and cardiovascular disease in joint analysis of 
both sexes and cohorts.  
Phenotype Gene Variant rs# Modela Hazard ratio 
(95% CI) 
p-value 
Coronary heart disease ACE rs4293 G>A GG+AG vs. AA 1.42 (1.02-1.97) 0.0367 
 AGTR1 rs388915 A>G AA vs. AG+GG 0.45 (0.25-0.81) 0.0084 
 FGA rs2070018 A>G AA vs. AG+GG 1.55 (1.11-2.17) 0.0101 
 FGA rs2070018 A>G AA>AG>GG 1.48 (1.09-2.03) 0.0133 
 IL6 rs1554606 T>G GG vs. GT+TT 1.43 (1.02-2.00) 0.0369 
 IL6 rs1800795 C>G CC+CG vs. GG 0.71 (0.52-0.99) 0.0424 
Cardiovascular disease FGA rs2070018 A>G AA vs. AG+GG 1.49 (1.11-2.02) 0.0091 
 FGA rs2070018 A>G AA>AG>GG 1.45 (1.09-1.91) 0.0097 
 FGA rs6050 T>C CC vs. CT+TT 1.60 (1.05-2.42) 0.0279 
 FGB rs1800788 C>T CC>CT>TT 0.81 (0.66-0.99) 0.0376 
 FGB rs2227439 C>T CC vs. CT+TT 1.35 (1.01-1.80) 0.046  
 FGG rs2066861 C>T CC+CT vs. TT 0.62 (0.40-0.94) 0.0247 
 IL6 rs2069827 G>T GG vs. GT+TT 1.30 (1.00-1.68) 0.0495 
a Time-to-event analysis, adjusted with geographic region, cohort, HDL-C, non-HDL-C, body mass index, 
mean blood pressure, smoking status, history of diabetes 
 
5.3.2 Joint analysis of interleukin 6 -related genes 
Since the IL6 -related genes form a biologically meaningful pathway, we analysed 
the joint effects of all 30 SNPs in these genes and the risk for incident CHD and 
CVD using Cox’s proportional hazard model. We did not include analysis of 
ischemic stroke due to the small number of individuals. The analysis revealed one 
SNP pair FGA: rs2070018 and IL6: rs2069827 in which the carriers of variant 
alleles from both SNPs had significantly lower risk for CHD and CVD than 
individuals who carried variant allele from only either of the SNPs. The analysis 
included 30 CHD and 43 CVD cases with variant alleles from both SNPs, and 182 
CHD and 242 CVD cases with variant allele from either of the SNPs and 174 CHD 
and 219 CVD cases with no variant alleles.  
In the combined analysis of both cohorts and sexes the risk for CHD was 61.5% 
lower (uncorrected p-value 0.0002) and 58.7% lower (p = 0.0001) for CVD for 
individuals with variant alleles from both SNPs. The difference was similar in both 
cohorts in combined analysis of both sexes (Figure 14). The risk for individuals 
carrying variant alleles from both SNPs compared to those who did not carry variant 
alleles from either of the SNPs was 0.37 (0.22-0.61) for CHD and 0.41 (0.26-0.64) 
for CVD when both sexes and cohorts were analyzed together. The risk was not 
different between those who carried the variant allele from either of the SNPs and 
 84 
 
those who carried none. The results of joint analysis of both sexes and cohorts for 
CHD and CVD, and combined analysis of both male cohorts for CVD had a FDR 
value less than 10%. A clear trend of association in the two variants FGA: 
rs2070018 and IL6: rs2069827 in sex- and cohort stratified analysis gives further 
support for the joint effect of both variants. The variant alleles of both SNPs showed 
evidence of a protective effect on the risk for CHD, ischemic stroke and CVD 
(Figure 15). 
 
 
 
 
 
 
 
Figure 14. Association of joint effects of SNPs FGA: rs2070018 and IL6: rs2069827 
with coronary heart disease and cardiovascular disease. Results with FDR value  10% 
are expected to include 90% true positive findings. 
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5.3.3 Association with CRP, IL6 and fibrinogen levels 
In addition to the risk for CVD, we investigated whether genetic variation in genes 
CRP, FGA, FGB, FGG and IL6 associated with the levels of the respective gene 
products in subcohort individuals free of CVD at the baseline. Furthermore, we 
investigated the association between IL6 gene variants and the levels of fibrinogen 
and IL6, and between all genes in study III and CRP levels. A rare variant allele of 
synonymous SNP rs1800947 (frequency = 0.06) in the second exon of the CRP gene 
associated strongly with decreased CRP concentration in combined analysis males 
Figure 15. Variant allele associated risk of SNPs FGA: rs2070018 and IL6: rs2069827 for 
coronary heart disease, ischemic stroke and composite end-point cardiovascular disease 
separately in the two cohorts and sexes. 
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from both cohorts (p = 0.0001). The trend of the association was similar in women 
(Figure 16). 
 
The results from linear regression models for the fibrinogen levels, revealed a 
variant rs2070018 in the FGA gene, which showed evidence of association, the 
variant allele carriers having lower levels. The association was strongest in the joint 
analysis of both sexes in the FINRISK 92 cohort (p = 0.004, uncorrected) and the 
trend was similar in other subgroups analysed (Figure 18). The fibrinogen 
concentration was not available from women in the FINRISK 97 cohort. We found a 
trend of an association also for additive effect of variant rs1800792 in the FGG gene 
in the FINRISK 92 cohort. Each variant allele increased the fibrinogen concentration 
in the joint analysis of men and women by 0.2 mg/l (p = 0.009, uncorrected). The 
trend was similar in both men and women but evident only in the FINRISK 92 
cohort (Figure 17). The LD between these two variants in the fibrinogen locus is low 
(r2 = 0.08) suggesting that these associations did not stem from high correlation 
between the variants. Interleukin 6 gene variants did not associate with CRP, 
fibrinogen or IL6 levels at p < 0.01.  
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Figure 16. Association of CRP gene variant rs1800947 with high 
sensitivity CRP levels in subcohort individuals free of baseline 
CVD. Significance level: p<0.05*, p<0.01**, p<0.001*** 
(uncorrected), for the difference between the two groups. 
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Figure 18. Association of variant FGA: rs2070018 with the 
fibrinogen levels in subcohort individuals free of baseline CVD. 
Significance level: p<0.05*, p<0.01**, p<0.001*** (uncorrected), for 
the difference between the two groups. 
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Figure 17. Association of variant FGG: rs1800792 with the 
fibrinogen levels in subcohort individuals free of baseline CVD. 
Significance level: p<0.05*, p<0.01**, p<0.001*** (uncorrected), 
for trend. 
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5.3.4 Sex-specific association with CVD risk factors 
Several of the IL6 pathway genes were associated with CVD risk factors differentially 
in men and women. Particularly, a variant allele of SNP rs1800792 in the promoter 
region of the FGG gene associated only in women in an additive fashion with 
decreased levels of HDL-C and higher BMI (uncorrected p-value for interaction  
0.01) (Table 14). Another variant in the fibrinogen gene cluster FGA: rs2070006 
associated also with HDL-C only in women with an unadjusted interaction p-value of 
0.0001. Table 14 presents suggestive sex-genotype interaction results only for IL6 -
related genes. The interaction test was performed for all 172 SNPs in study III in three 
different genetic models for CHD and CVD end-points and quantitative traits: mean 
blood pressure, non-HDL-C, HDL-C, triglycerides, total cholesterol, CRP, BMI and 
WHR. For sex-genotype interaction results with p  0.01 the estimated proportion of 
true positive findings is 30% but with the additional criterion of nominal association at 
the p  0.01 level in time-to-event analyses or at the p < 0.01 level in quantitative 
analysis in either sex in joint analysis of both cohorts, the expected proportion of true 
positive findings is likely to be greater. 
 
 
Table 14. Genotype-sex interaction in interleukin 6 -related genes with quantitative CVD 
risk factors. Results from linear regression analysis, adjusted for geographic region, cohort 
and age showing evidence of association in either sex (uncorrected p  0.01) and genotype-
sex interaction (uncorrected p  0.01). 
  Mean value for minor homozygotes / 
heterozygotes / major homozygotes 
 
Gene: variant Model Women p-valueb Men p-valueb p-value 
interactiona/b 
Body mass index (kg/m2)      
ACE: rs4320 G>A additive 29.0 / 27.8 / 26.5 0.003 27.5 / 27.6 / 28.1 0.2 0.0009 
FGG: rs1800792 T>C additive 30.8 / 28.2 / 26.7 0.0005 27.9 / 27.6 / 27.7 0.9 0.002 
HDL cholesterol (mmol/l)      
CRP: rs1205 C>T recessive 1.77 / 1.46 / 1.52 0.0008 1.28 / 1.23 / 1.24 0.3 0.02 
FGA: rs2070006 C>T additive 1.73 / 1.53 / 1.38 0.0002 1.24 / 1.23 / 1.29 0.2 0.0001 
FGG: rs1800792 T>C additive 1.38 / 1.46 / 1.62 0.004 1.20 / 1.28 / 1.24 1.0 0.01 
a Interaction p-value tests the null hypothesis that the genotype effects in regression analysis in men and 
  women do not differ from each other. 
b Uncorrected p-values. 
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5.3.5 Sex-specific association of other candidate genes  
In study III, we observed several sex-specific interactions between genetic variants 
and the risk for CHD, ischemic stroke or CVD. First, we confirmed a previously 
reported sex-specific association with increased risk for CHD and CVD only in 
women for variant USF1: rs2774279 (Komulainen et al. 2006). Furthermore, three 
variants in the SEPS1 gene haplotype H4 showed evidence of association with 
increased risk for ischemic stroke only in women as described in study II, and we 
observed evidence for sex-genotype interaction for them (uncorrected p-values for 
interaction 0.02-0.007). Other genes with evidence of sex-specific effect at p  0.01 
and evidence of association at p  0.01 (uncorrected) were for coronary heart 
disease: CPB2 and F13A1 in women, and for cardiovascular disease: CPB2, and 
LPIN1 in women. Furthermore, we observed several associations for quantitative 
risk factors only in either sex with evidence of association at p  0.01 and genotype-
sex interaction at p  0.01 (uncorrected). In male subcohort individuals without 
CVD at the baseline, a LPIN1 gene variant showed evidence for association with 
total cholesterol, a APOBEC2 gene variant with LDL-C, a F5 gene variant with 
triglycerides and a SERPINE1 gene variant with mean blood pressure. In women we 
observed evidence of association for F5, LPIN, THBD and USF1 gene variants with 
CRP, for F13A1 and USF1 gene variants with BMI, and for three ICAM1 gene 
variants with WHR.  
5.3.6 Power analysis of the case-cohort set 
Understanding the power of the study is critical to the correct interpretation of the 
analysis results from an association study. We estimated the power of the case-
cohort set separately for men and women by combining the two FINRISK cohorts 
but not adjusting for number of variants. Together the simulation model for incident 
CVD included 881 men (409 cases) and 372 women (177 cases). Simulation of 
covariates (the same as used in regression modelling) in 5000 independent data sets 
with six different combinations of allele frequencies and effect sizes revealed that 
the power of the study is quite low for each sex separately while in joint analysis we 
had approximately 70% power to detect a hazard ratio of 1.3 (Figure 19) (Kulathinal 
et al. 2007). With this power, we estimated posterior odds for a true finding amongst 
the 27 independent genes in study III of 6:1, if we expect to observe two true 
associations (The Wellcome Trust Case Control Consortium 2007). 
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5.3.7 Conclusions and discussion of Study III 
In a summary, we found evidence of an association between genetic variation in the 
IL6 pathway and the risk for CVD and CVD risk factors. In the IL6 gene, variant 
rs2069840 associated with an increased risk for CVD in men while another 
(rs2069827) showed a trend of an association for a decreased risk. These two variants 
are not in tight LD with each other (r2 = 0.08). Furthermore, the second variant was 
jointly associated with decreased risk of CHD and CVD with a variant rs2070018 in 
the FGA gene downstream in the IL6 pathway. Unfortunately, the number of 
individuals homozygote for both variants was too small to allow more detailed 
analysis of a possible interaction model behind this association. Haplotypes in the IL6 
gene promoter area have previously been associated with the transcriptional regulation 
of the gene but have not included the IL6: rs2069827 variant, which is located ~1.3kb 
upstream of the gene. The variant is the sole representative of the haplotype bin it 
resides in according to the SeattleSNPs database. It is thus likely that the association 
with CVD may involve transcriptional regulation of IL6 and that this variant adds 
more to the previously studied haplotype diversity in the regulatory region of the gene. 
Figure 19. Estimated power of the FINRISK case-cohort set. Power was estimated for 
men, women and joint analysis at three different allele frequencies 0.05, 0.2 and 0.4, and 
four different hazard ratios 1, 1.16, 1.35 and 1.82 in 5000 simulations. 
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The FGA: rs2070018 variant is located 37 bp downstream of the fourth exon of the 
FGA gene and can putatively alter the splicing of the fourth intron. Alternatively, it 
may present signal from a variant in a repeat region in the promoter area of the FGA 
gene (rs2070008) which tags the same haplotype bin or signal from variant rs2227439 
in the FGB gene, which is also located in a repeat region (r2=0.78). The risk-lowering 
effect of FGA: rs2070018 may be mediated through its association with lower levels 
of fibrinogen. The joint effect of these two variants on the risk for CVD may be 
mediated through altered availability and constitution of IL6 and fibrinogen alpha 
transcripts, a new interesting pair of molecules that have not together been previously 
associated with CVD. 
G e n e t i c  v a r i a n t s  i n  t h e  i n t e r l e u k i n  6  g e n e  
Polymorphisms in the IL6 gene have been inconsistently associated with MI, CHD 
and the acute coronary syndrome (Rauramaa et al. 2000, Georges et al. 2001, 
Humphries et al. 2001, Jenny et al. 2002, Sie et al. 2006, Barbaux et al. 2007). 
Recently, Mälarstig and co-workers (2007) analysed some of the same variants as 
we did in our study (-572G>C (rs1800796), rs2069827 and two proxies for -
174G>C (rs1800795)) also selecting SNPs representing haplotype bins in the 
SeattleSNPs database. In their study of 3027 non-ST elevated ACS patients, who 
received dalteparin treatment or placebo, and 447 controls they concluded that 
variation in the IL6 gene does not associate with ACS.  
The IL6 promoter region haplotype carrying the variant allele of SNP -174G>C has 
previously been associated with decreased ex vivo production of IL6 and decreased 
affinity for nuclear proteins (Rivera-Chavez et al. 2003). The findings have been 
inconsistent in regard to -174G>C and circulating levels of IL6 (Fishman et al. 1998, 
Sie et al. 2006). In this study, we were able to analyze the effect of genetic variants 
on serum IL6 concentration in 309 population-based controls free of baseline CVD 
from the FINRISK 92 cohort. None of the five variants in our study associated 
consistently and significantly with serum IL6 levels, but carriers of the C allele of 
SNP -174G>C tended to have lower levels. Although the participants were all 
studied in the semi-fasting state, the diurnal and intra-individual variation in the 
levels of IL6 and differences in the time before the last meal may have confounded 
these analyses (Dugue and Leppänen 1998, Undar et al. 1999). 
G e n e t i c  v a r i a n t s  i n  t h e  f i b r i n o g e n  g e n e s  
Studies on SNPs and haplotypes in the fibrinogen gene cluster and fibrinogen 
concentration have been conflicting and both negative and positive findings have been 
presented (Thomas et al. 1995, Mannila et al. 2004, Mannila et al. 2005, Kathiresan et 
al. 2006b, Keavney et al. 2006, Mannila et al. 2006). Similarly, there has been several 
positive (Boekholdt et al. 2001, Mannila et al. 2005, Mannila et al. 2006, Mannila et 
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al. 2007) and negative (Fox et al. 2004, Mannila et al. 2004, Kathiresan et al. 2006b, 
Keavney et al. 2006, Uitte de Willige et al. 2006, Zee et al. 2006) association reports 
on genetic variants in the cluster and the risk of MI, CHD or increased carotid intima 
media thickness. In this study, we observed an association between fibrinogen 
concentration and two variants FGA: rs2070018 and FGG: rs1800792. Interestingly, 
two variants from the fibrinogen gene cluster FGA: rs2070006 and FGG: rs1800792 
associated in women with levels of HDL-C, and the FGG variant also with BMI. 
Furthermore, the same variant associated at the p < 0.05 level for interaction with 
triglycerides and WHR. There is no apparent rationale of how the fibrinogen gene 
polymorphisms would regulate lipid metabolism and the result may represent 
statistical fluctuation. It is known, however that hypercoaguability and 
hypofibrinolysis coincide with lipid disorders and that obesity promotes prothrombotic 
and hypofibrinolytic state and dyslipidemia (Darvall et al. 2007). Apart from the 
variant FGA: rs2070018, variants in the FGA, FGB and FGG genes did not associate 
with the risk of CHD, ischemic stroke or CVD.  
G e n e t i c  v a r i a n t s  i n  t h e  C R P  g e n e  
Previous studies on the CRP gene locus and the association with CVD have been 
conflicting. (Miller et al. 2005, Kardys et al. 2006, Lange et al. 2006) In this study (III), 
we did not observe any evidence of association for any of the six CRP variants studied.  
Several variants in the CRP gene have been associated with the baseline or 
stimulated serum CRP levels (Miller et al. 2005, Kathiresan et al. 2006a). The 
association reports are most consistent for a tri-allelic SNP -286C>T>A (rs3091244) 
in the promoter region of the CRP gene. Both variant alleles T and A are associated 
to higher CRP levels in Caucasian populations. The SNP disrupts an E-box binding 
site for basic helix-loop-helix transcription factors such as USF1, USF2, Myc and 
Max and the T-allele has been shown to affect binding of nuclear proteins (Szalai et 
al. 2005). In this study, we investigated the association of the tri-allelic SNP by 
using two variants rs1130864 and rs3093075 as surrogates for the alleles A and T, 
respectively. We did not find a significant association at p  0.01, although the 
variant allele carriers of rs3093075 (corresponding to the A-allele of -286C>T>A) 
tended to have higher levels of CRP. In concordance with earlier studies (Carlson et 
al. 2005, Lange et al. 2006), we observed an association with variant allele of SNP 
+1059G>C (rs1800947) and decreased CRP levels. In our study including 172 
variants, this association was one of two results with a FDR value <10%. 
G e n e t i c  v a r i a n t s  i n  t h e  R A S  s y s t e m  
Several studies have reported genetic analyses of the renin-angiotensin-system 
focusing mainly on three polymorphisms ACE: I/D, angiotensinogen M235T and 
AGTR1: A1166C and their interaction. The Beijing atherosclerosis study 
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investigated more extensively the sequence variation in the AGTR1 gene and found 
three SNPs (rs275650, rs2276736 and rs5182), but not A1166C, all of which 
associated with myocardial infarction (Su et al. 2004). Recently the variant allele of 
A1166C has been shown to produce less mRNA than the more common allele and 
that the 3’ region of the gene, where this variant is located, associates with metabolic 
syndrome traits (Abdollahi et al. 2007). In this study (III), the ACE: I/D 
polymorphism did not associate with CHD, ischemic stroke or CVD, neither did it 
have synergistic effects with variants in the AGTR1 gene. In the AGTR1 gene, we 
observed an association for increased risk for CHD with an intronic SNP rs388915 
in a joint analysis of men and women. Although the results were not significant in 
sex-stratified analyses, the trend of the effect was similar in both sexes. AGTR1: 
A1166C and other variants in the AGTR1 gene were not associated with these end-
points and the variant rs388915 was not in significant correlation with any of the 
other variants. 
S e x - s p e c i f i c  a s s o c i a t i o n  r e s u l t s  
This study also observed evidence of genotype-sex interaction both for the risk for CVD 
and CVD risk factors. Generally, we identified more associations in women than in men. 
We confirmed that these results do not stem from just either cohort by conducting a 
cohort-genotype interaction test. There are a few possible reasons for the female-
specificity of our findings. First, the aetiology of the disease is somewhat different for 
females and males. The biological basis for this difference comes from: 1) differences in 
the genetic make-up as represented by the XX and XY sex chromosomes, 2) differences 
in distribution of CVD risk factors, 3) the effects of sex hormones, 4) anatomical and 
physiological differences in fat distribution and insulin resistance (Mittendorfer 2005a), 
lipid metabolism (Mittendorfer 2005b), cardiovascular function (Leinwand 2003) and 
gene expression (Rinn and Snyder 2005).  
The differences in distribution of CVD risk factors and the sexual dimorphism in the 
risk for CHD has been studied before in the Finnish population. In a study by 
Jousilahti and co-workers (1999), the differences in CHD risk factors, particularly 
HDL-C to total cholesterol ratio, explained approximately half of the observed 
difference in the risk for CHD. For some risk factors, the difference diminished with 
increasing age, suggesting the difference in the size of the effect should also diminish. 
It is, however, possible that these risk factors have a larger effect in men because of 
cumulative effects during longer periods of exposure. Although the prevalence of 
positive family history of CHD does not differ between sexes in the Finnish 
population (Jousilahti et al. 1996a), it is plausible that, in addition to unaccounted 
differences in nutrition, alcohol intake and physical activity, genetic factors contribute 
to the remaining half of the observed difference in the risk for CHD.  
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It has been shown for many human diseases, that the gender-dependent differences 
in the progression and extent of disease are partially explained by sex hormones. 
The differential effects in gene expression in somatic tissues may lead to gender 
specific susceptibility to disease (Rinn and Snyder 2005). In women, oestrogen has 
several protective effects against CHD. It induces favourable effects of long-term 
regulation of arterial blood pressure in the kidney and inhibits many age-related 
vascular remodelling processes such as VSMC proliferation and endothelial 
dysfunction. In addition, oestrogen lowers cholesterol and improves vascular tone 
(Dubey et al. 2005). It is thus possible, that a complex interplay between a hormonal 
milieu and agents that induce inflammation will have an impact on the expression of 
the genes associated with CVD. 
S t r e n g t h s  a n d  l i m i t a t i o n s  
This study is one of the few, which have investigated extensively common genetic 
variation and joint effects of a set of candidate genes of CVD that form a biologically 
meaningful pathway. In the era of GWA, this type of study is likely to become more 
common when we start to dissect how the new candidates and candidate pathways 
emerging from the GWAs contribute to the risk for common diseases.  
None of the presented findings in study III represent strong evidence of association. 
There are a few possible reasons for this. The power was somewhat limited first, due 
to relatively small number of cases especially when analysing the two sexes 
separately and second, due to very large number of tests. Although we utilized two 
large prospective cohorts each followed for several years, we were able to include in 
our analysis only 154 female incident CVD cases and 373 male cases. This 
represents the down-side of case-cohort studies: even when using large population 
based cohorts and focusing on a common disease is it hard to be able to include 
thousands of incident cases in the analyses. Collaborative studies, such as the 
Morgam project (Evans et al. 2005) merging information from several case-cohort 
studies would provide a solution for this problem provided that between studies 
heterogeneity is not very large. Also, replication in several independent studies 
would provide support for validity of the results. Although cohort studies may not be 
very efficient in collecting large numbers of cases they have the advantage of being 
able to model more precisely without biases encountered in retrospective studies the 
prospective risk effect of strong risk factors that may be affected by the disease or 
lifestyle changes or have a long latent period (Manolio et al. 2006).      
Our study aimed to investigate genes with a biological hypothesis of an effect on 
CVD and included parts of pathways with close relationships between the genes. 
The association of most of these genes was studied using common variants 
describing the common haplotype structure of the gene. Recent large scale genetic 
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association studies and meta-analyses have shown that the risk effect of the common 
associating variants is quite small, in the range of 1.1-2 (Lohmueller et al. 2003, 
Altshuler and Daly 2007). Our study, although describing well the common 
variation within these genes, may have not been powerful enough to detect such 
small effects even though the selection of biological candidates increased our a 
priori probability to detect association. Also, the relative heterogeneity in CVD 
phenotype encompassing ACS and ranging from unstable angina to ST-elevation MI 
may have influenced the power of this study. More homogenous phenotype 
restricting the study only to, for example, definite myocardial infarctions might have 
improved the odds.  
Both the number of genotyped variants and analysed phenotypes was quite large in 
study III and we used a two-staged approach, FDR and additional nominal 
association limits to control for the number of tests. In addition, we compared results 
from the two cohorts in joint analysis of IL6 -related genes. From all of the tests, 
only two single SNP association results had a FDR value <10%. In this type of study 
with non-independent genetic markers, non-independent genes and a hierarchical 
nature of the data, FDR is possibly the best method to account for the multiple tests, 
although it is far from optimal. Replication in additional cohorts would have 
increased the probability of true positive association. 
This study should be considered as being exploratory in nature and its findings should 
be replicated in other population-based studies. Based on the results of this study, we 
can not definitely exclude any of these genes from being a candidate gene for CVD. 
However, this study utilized two separate population cohorts and prospective design 
reducing the potential of selection and information bias in the study. The results 
consistent with earlier findings and clearly present in both cohorts, such as the 
association between the CRP variant rs1800947 and CRP levels, lend further support 
to the validity of the study design and its findings. Taken together, these results 
indicate that the interleukin 6 pathway may be involved in the pathogenesis of CVD at 
many levels and argue for further studies, especially in women.  
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6 CONCLUDING REMARKS 
We showed in this thesis that certain inflammatory genes contribute to the risk for 
CHD, ischemic stroke or CVD and interestingly most of the identified associations 
were among women. Furthermore, we showed that inflammatory factors and traits 
are associated with the DNA yield from whole blood samples.  
During the course of this study, the available tools for genetic epidemiology have 
developed enormously. The publicly available full sequence of the human genome 
and many other organisms including primates has enabled scientists to compare 
sequence homology between species to identify conserved regions and 
polymorphisms and putative regulatory motifs. Together with the expanding 
catalogue of human polymorphisms and more detailed haplotype construction, this 
information has made the attempt to identify sequence variation contributing to the 
disease susceptibility more advanced.  
Although the tools are becoming more easy to use and available to many research 
groups, genetic epidemiology faces huge challenges in terms of multiple testing with 
non-independent markers, genes and overlapping phenotype categories. New tools 
are definitely required to account for the number of tests statistically since 
increasing the number of samples indefinitely will not be a sustainable option. The 
accuracy of the results from genetic epidemiological studies will increase with 
increasing homogeneity in phenotype measurement and definition, and although 
collaborative studies with a number of participating centres will aid in increasing the 
number of individuals in the study, unless carefully accounted for via rigorous study 
design, they may result in greater noise in the genetic signal than aiding in tackling 
multiple testing problems due to increase in heterogeneity in measured phenotypes. 
During the follow-up period of this study, the implementation of troponin 
measurements in Finland between 1997-2000 improved the diagnosis of myocardial 
infarction (Salomaa et al. 2005). Although this has increased the precision of the 
diagnosis, it has mostly done it in individuals who would have been diagnosed for 
ACS also with older diagnostic tools. It is thus unlikely, that this would have 
substantially affected the heterogeneity in the CHD phenotype of this study. 
One drawback of both case-control and -cohort studies is the susceptibility to 
unobserved differences in allele frequencies in subgroups of the base population, i.e. 
population stratification. Population based cohort studies are less vulnerable to this 
than carelessly selected case-control studies. This phenomenon causes overestimates 
in the effect sizes of the associating allele and false positive results if the causative 
variant is overrepresented, or if the penetrance of this variant is higher in a subgroup 
 97 
 
(Setakis et al. 2006). An Icelandic study observed that in their population, which had 
been thought to be very homogenous, there was evidence of significant population 
stratification (Helgason et al. 2005). Differences in allele frequencies are also 
evident in the Finnish population (Pastinen et al. 2001). Without extensive genotype 
information from the population, it is impossible to correct for population 
stratification with sampling strategies in population-based studies. The use of family 
members as controls and novel statistical methods, such as, genomic control offer 
some help (Terwilliger and Ott 1992, Devlin et al. 2001). Simulation studies 
indicate, however, that statistical association methods using the χ2 statistic are quite 
robust against population stratification and significant excess of false positive 
findings occur only when there are two very different subgroups in the analysis 
(Setakis et al. 2006). In our study, we were able to use the knowledge of 
geographical east-west difference in allele frequencies present in Finland and 
adjusted or stratified the analysis accordingly thus reducing the likelihood of false 
positive findings due to population stratification. 
Other challenges are common to traditional epidemiology. It has been shown that 
some risk factors change over time (Zavaroni et al. 2002), and that although cross-
sectional baseline measurements do provide good estimates of the risk, updated 
measurements offer better predictive power (Karp et al. 2004). It may thus also be 
justified to invest in repeated measurements and longitudinal study design in addition 
to large-scale genotyping in traditional case-control or case-cohort designs. More 
precise models, which would account for the traditional risk factors, might help to 
tease out the small genetic effects accounting for the rest of the phenotypic variability 
and enable investigation of so-called variability genes in addition to level genes. 
Novel approaches including expression quantitative trait mapping, and the use of 
new intermediate phenotypes like IMT and non-invasive measures of endothelial 
function or arterial stiffness, are likely to advance the field of cardiovascular 
research in the future. Moreover, detailed analysis of the different plaque rupture-
like features currently available in murine models will enhance our understanding of 
the processes leading to acute myocardial infarction events (Falk et al. 2007). 
So far, the variants identified in various studies searching for susceptibility genes for 
common traits have been shown to have a rather small effect at the population level. 
However, although at this point the variants do not add substantially to the 
predictive power of traditional risk factors, they may prove to be clinically useful at 
the individual level. Also, with accumulating knowledge of several variants, the 
combined information of them may one day add to the predictive power. 
In this study we identified several suggestive associations in the selected CVD 
candidate genes with relatively small effects. Common to these findings was marked 
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sexual polarization of the results most of the findings being evident in women only. 
In study II variation in the SEPS1 gene locus associated with the increased risk for 
CHD and ischemic stroke in women and study III confirmed significant genotype-
sex interaction for haplotype H4 associated variants. Study III identified many more 
associations with evidence of sex-genotype interaction. Unfortunately, there are very 
few large scale association studies on cardiovascular disease in women and even 
fewer have formally tested sex-genotype interaction making it hard to compare our 
results with others'. In addition to the hormonal difference, it is possible that subtle 
genetic effects can be more readily identified in women due to a smaller risk factor 
load than in men. We hope that study III will promote collection and analysis of 
samples with more female CVD cases. 
Based on this study, we can conclude that inflammation and genetic variation in 
genes related to inflammation play a minor but a consistent role in the risk for CVD, 
especially in women. This study suggests that new genetic epidemiological studies, 
in which participants are not ascertained based on the availability or amount of the 
DNA sample, are warranted in this field.  
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